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Abstract
In colorectal cancer, the selection of patients for adjuvant chemotherapy is currently 
based on the Dukes’ stage. However, more prognostic markers are needed to allow 
better selection of patients whose risk of future recurrence is sufficiently high to 
warrant chemotherapy.
The aims of this study were to investigate the expression and prognostic value of 
Human Epidermal Growth Factor Receptor-2 (HER-2) and microvessel density 
(MVD) in patients with colorectal cancer and their relationship with clinico- 
pathological parameters. HER-2 is over-expressed in a number of epithelial cancers.
The prognostic role of HER-2 has been established in breast cancer but remains 
controversial in colorectal cancer. The expression pattern and prognostic value of 
HER-2 was investigated in 170 patients with Dukes’ B or C colorectal cancer, who 
underwent radical surgery between 1990 and 1998. The anti-HER-2 monoclonal 
antibody HM64.13 and a standard avidin-biotin peroxidase detection system were 
used. Overall, 87% and 41% of cases showed cytoplasmic and membranous HER-2 
immunostaining, respectively.
In the Dukes’ C cancers, a significant survival benefit was observed in those patients 
whose tumours showed cytoplasmic HER-2 (HR 0.46, Cl95 0.24-0.87), with no 
association between membranous HER-2 over-expression and clinical outcome. The 
other independent prognostic factors in the Dukes’ C group were apical node 
metastases, grade 3 tumours, and depth of invasion. No significant prognostic 
association was seen in the Dukes B patients.
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Using the monoclonal antibody CD31, MVD did not seem to be a predictor of poor 
outcome in this study, and there was no association found between MVD and HER-2 
overexpression.
These data suggest that there may be a correlation between cytoplasmic HER-2 
overexpression and better prognostic tumours. Furthermore the high level of 
membranous HER-2 in colorectal cancer could make it an ideal target for monoclonal 
antibody-based therapy.
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Chapter one Introduction
Chapter One 
Introduction
1.1 Background
Carcinogenesis is a complex, multistep process that leads to transformation of a 
normal cell into a cancerous phenotype. This process of transformation involves a 
number of prerequisite steps which may start with six or more independent 
mutational events [Fearon ER and Vogelstein B, 2001]. The mutated cells may then 
have a decreased responsiveness to the intercellular and intracellular signals that 
maintain their architecture and regulate their growth. These mutational changes 
result in dysregulation of the cell cycle, loss of tumour suppressor genes, genomic 
instability, and resistance to apoptosis. The potential result of all these genetic 
alterations is unregulated cell growth and proliferation.
1.2 Colorectal Cancer
Colorectal cancer is among the highest causes of cancer mortality in the Western 
world, being second only to lung cancer, and is responsible for some 400,000 deaths 
per year [Pisani P et al., 1993]. In 1998, in the United Kingdom (UK), there were 
34,600 new cases of colorectal cancer [Office of National Statistics, 2001]. In the UK, 
colorectal cancer is the second most common cancer in females, after breast cancer, 
whilst it is the third most common cancer, after lung and prostate cancer, in males.
Overall, the incidence of colorectal cancer in men and women is the same, but colon 
cancer is more common in females whilst the incidence of rectal cancer is higher
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amongst males. In 2000, there were 16,250 deaths from colorectal cancer in the UK, 
with higher mortality rates in men. The incidence trends for colorectal cancer in the 
UK differ in men and women. Whereas the incidence of colorectal cancer in men has 
increased by 20% since the late 1970’s, female rates have remained fairly stable. 
Mortality is declining at similar rates for men and women [Office of National 
Statistics, 2001].
1.3 Current Chemotherapy used in Colorectal Cancer
Despite the majority of patients with colonic cancer apparently having complete 
microscopic clearance of their disease by resection, about half of these patients will 
recur at a distant site, which suggests that they had micrometastases present at 
diagnosis. Adjuvant chemotherapy (i.e. that given after surgery) is given to those 
patients who are considered at high risk of micrometastases to try and eradicate 
these circulating cancer cells before they become established. 5-Fluorouracil (5-FU) 
has been the principle drug of choice in a number of different schedules for the 
treatment of colorectal cancer since its introduction in the 1950s. It is a pro-drug 
which is converted intracellularly to various metabolites which inhibit the enzyme 
thymidylate synthase, thereby inhibiting DNA and RNA synthesis. However, 5-FU 
has modest activity as a single agent, and its activity is maximised by the addition of 
folinic acid (FA), which enhances the inhibitory effects of 5-FU on thymidylate 
synthase, and increases the tumour response rate, typically from 11% to 23% 
[Advanced Colorectal Cancer Meta-analysis Project, 1992].
When used in the adjuvant setting, 5-FU/FA chemotherapy results in approximately 
6% increase in survival at 5 years [International Multicentre Pooled Analysis of Colon
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Cancer Trials (IMPACT) investigators, 1995; O'Connell M et al., 1997]. Therefore 
new drugs have been developed with the aim of improving the outcome of those 
colorectal cancer patients who have undergone radical surgery. Oxaliplatin is one 
such chemotherapeutic agent. It is a platinum-based cytotoxic drug that forms DNA 
adducts, preventing replication and hence cell division, and in vitro studies show it to 
act synergistically with 5-FU in colorectal cell lines. A number of randomised 
controlled trials (RCTs) have shown improved tumour response rates (from under 
23% to over 50%), and improved time to progression using this combined regimen of 
oxaliplatin/5-FU/FA in metastatic colorectal cancer, but they have failed to show an 
improved overall survival [De Gramont A et al., 2000; Giacchetti S et al., 2000; Levi 
FA et al., 1997]. An adjuvant study examining the benefit of 5-FU/FA/oxaliplatin (over 
5-FU/FA alone) has reported a significant 3-year disease-free survival, but no overall 
survival benefit so far [De Gramont A, 2003]. Further follow-up data is probably 
needed before this regimen will become the standard adjuvant treatment in the UK.
Irinotecan is another drug which acts on a different molecular target. It is a 
topoisomerase I inhibitor, a DNA-unwinding enzyme essential for cell division. 
Irinotecan binds to the enzyme and stabilises the strand break. Multiple RCTs, in 
advanced colorectal cancer, using irinotecan and various schedules of 5-FU/FA have 
shown a statistically significant improvement in tumour response rate from around 
20-30% with 5-FU/FA alone to approximately 40-50% with the addition of irinotecan 
[Douillard JY et al., 2000; Saltz LB and et al, 2000]. These same trials have shown a 
significant improvement in the time to progression and median survival by 2-3 
months. The result of the adjuvant trial of irinotecan/5-FU/FA chemotherapy 
(ICCART) is still awaited, but on the basis of current data, this chemotherapy
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regimen is licensed for adjuvant use already in a number of countries, including the 
United States of America.
Two oral pro-drugs of 5-FU, capecitabine and UFT (pro-drug ftorafur and uracil), are 
oral fluoropyrimidines that are licensed for use in the UK as alternatives to 
intravenous 5-FU, for use as first-line monotherapy in metastatic colorectal cancer. 
Currently, there are on-going studies investigating the substitution of infusional 5-FU 
for these new oral chemotherapies, in the adjuvant treatment of colorectal cancer.
Although a small proportion of patients with metastatic disease will be cured as a 
result of salvage resection of their metastases, the majority will die of their disease. 
So despite advances in surgical techniques, and chemotherapeutic strategies, 
colorectal cancer remains a major cause of cancer mortality. The modest 
improvements in survival seen with the newer chemotherapies, over the use of 5- 
FU/FA alone, suggests that there is not only a need to develop more effective drugs, 
but a need to combine the conventional chemotherapies with other agents that are 
active via alternative molecular pathways, for example receptor blockade and/or 
angiogenesis and enzyme inhibition.
1.4 Prognostic Factors in Colorectal Cancer
Currently, prognosis depends on pathologic staging of the disease. The Dukes’ 
staging system is one of the frequently used systems in the UK (Table 1.1), and 
currently remains the most important independent prognostic factor [Dukes CE and 
Bussey HJR, 1958]. The five-year survival for colorectal cancer ranges from about 
85% for Dukes’ A patients to less than 5% for Dukes’ D. However, the Dukes’
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Table 1.1. Overall survival of patients with colorectal cancer 
according to Dukes’ stage [National Health Service Executive, 
1999]
Dukes’ Stage 
(modified)
Definition Approximate 
frequency at 
diagnosis
5-year
survival
A Cancer localised within the 
bowel wall
10% 83%
B Cancer which penetrates the 
bowel wall
35% 64%
C Cancer spread to lymph nodes 26% 38%
D Cancer with distant spread 30% 3%
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staging system only allows stratification of the colorectal cancers into four (modified 
Dukes’ system) prognostic groups, with significant tumour heterogeneity within some 
of these sub-groups and variable clinical outcomes. For example, Dukes’ B cancers 
range from those which have only minimally breached the muscularis propria to 
those which have invaded into adjacent organs or other loops of colon. These 
tumours clearly will not have the same prognosis. However, when the difference 
between the depths of invasion of tumours is more subtle, the subjective opinions 
regarding their differences in prognosis become increasingly difficult.
The role of chemotherapy in the Dukes’ B cancers remains unclear [International 
Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators, 
1999;Mamounas E et al., 1999], and currently there is no clear consensus on the 
routine use of adjuvant chemotherapy in this group of patients [International 
Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators, 
1995;International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT 
B2) Investigators, 1999;Mamounas E et al., 1999]. The decision regarding adjuvant 
chemotherapy has often been based on the presence of factors indicative of a poor 
prognosis. Increasing age, poorly differentiated tumours and presence of 
lymphovascular invasion have been described as significant indicators of poor 
survival in colorectal cancer [Gastrointestinal Tumor Study Group, 1985]. Moreover, 
the presence of perforation or direct organ invasion has been shown to be an 
independent prognostic factor on multivariate analysis [Moertel CG et al., 1995b], 
The work of Quirke’s group demonstrated that involvement of the circumferential 
resection margin by residual microscopic disease was a significant indicator of local 
recurrence, independent of Dukes’ stage [Quirke P et al., 1986; Quirke P and Dixon 
MF, 1988].
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In contrast to the Dukes’ B tumours, the role of adjuvant chemotherapy has been 
established in Dukes’ C colorectal cancers in terms of conferring a significant 
survival benefit [Mamounas E et al., 1999]. However, the advantage of receiving 
adjuvant chemotherapy in Dukes’ C colorectal cancer is such that approximately six 
patients will achieve a survival benefit for every one hundred patients given 
chemotherapy. Therefore, even in this group of patients there are a significant 
number of patients receiving chemotherapy for no survival benefit. Furthermore, it 
should be noted that in the Intergroup study of 929 patients with Dukes’ C colorectal 
cancer, about 45% of patients treated with surgery alone were alive and disease-free 
after five years compared with approximately 65% who received adjuvant 
chemotherapy following surgery. This study indicated that nearly 50% of Dukes’ C 
patients did not apparently require chemotherapy, whereas 45% of patients recurred 
in spite of the chemotherapy regimen given [Moertel CG et al., 1995a]. Thus, it is 
clear that even in the Dukes’ C patients there is a great need for useful prognostic 
markers in order to identify those patients who need not be offered adjuvant 
chemotherapy. In the Dukes’ B patients, the need for useful predictors of distant 
failure will help select those patients who may benefit from adjuvant therapy. The 
need for more individualised therapy becomes increasingly important with the advent 
of more toxic chemotherapeutic agents such as Irinotecan and Oxaliplatin. However, 
without improvements in the efficacy of chemotherapies, better selection of patients 
alone will not improve the survival rates of colorectal cancer patients.
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1.5 Tumourigenesis and Molecular Markers
The development of colorectal cancer is thought to be dependent on multiple 
genetic events that involve alterations in specific genes - proto-oncogenes and 
tumour suppressor genes - that play an important role in the transition from normal 
mucosa through to the villous and more dysplastic adenoma, and then to frank 
carcinoma [Fearon ER and Vogelstein B, 2001]. The somatic alterations in these 
oncogenes include point mutations and alleleic losses on specific chromosomes. 
Gene amplification or re-arrangement does not seem to play a major role in 
oncogene activation in colorectal cancer [D'Emilia J et al., 1989].
A number of the genes involved in colorectal tumourigenesis have been identified -  
k-ras, FAP, DCC, and p53. Ras proteins belong to a family of 21 kilodalton (kDa) 
guanine nucleotide-binding proteins and are important in the control of cell growth 
and differentiation. The ras superfamily of proteins bind guanidine tri-phosphate 
(GTP) and hydrolyse it to guanidine di-phosphate (GDP), being active in the GTP- 
bound state and inactive in the GDP- bound state. Approximately 50% of 
carcinomas have been found to have k-ras gene mutations [Forrester K et al., 1987]. 
In contrast, such mutations are seen in fewer than 10% of adenomas less than 1 cm 
in size and the k-ras gene are thought to be an initiating event in a subset of 
colorectal cancers [Vogelstein B et al., 1988]. The loss of specific chromosomal 
regions (allelic loss) occurs frequently in colorectal cancer. This has been interpreted 
as evidence that these alleles carry tumour suppressor genes which are normally 
involved in regulating cell growth and differentiation such that when these genes are 
no longer present, the regulatory mechanism, and suppression of any neoplastic 
proliferation, is absent.
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An inherited predisposition to colorectal cancer occurs in familial adenomatous 
polyposis (FAP), in which hundreds of colorectal adenomas develop in an affected 
individual [Leppert M et al., 1987]. The locus linked to FAP has been mapped to 
chromosome 5q. The loss of a large portion of chromosome 17p has been seen in a 
large proportion of colorectal carcinomas, and this region contains the p53 gene, 
which is another tumour suppressor gene [Vogelstein B et al., 1988];[Baker SJ et al., 
1989]. The second most common region of allelic loss is chromosome 18q, which is 
lost in 70% of colorectal cancers [Vogelstein B et al., 1988]. The tumour suppressor 
gene identified in this region is the deleted in colon cancer (DCC) gene, which 
encodes a protein with significant homology to the cell adhesion family of proteins. It 
is thought that this gene is involved in the cell-cell and/or cell-matrix interactions, and 
that loss of this gene may affect these interactions
Although the relative roles of these genes in colorectal tumourigenesis have been 
detailed [Fearon ER and Vogelstein B, 2001], currently there is still controversy over 
whether these molecular markers provide significant prognostic information 
prospectively, and whether this information is complimentary to that obtained by the 
pathologist. Another intracellular protein which has been extensively investigated for 
its prognostic role in colorectal cancer is thymidylate synthase (TS), which is a rate- 
limiting intracellular enzyme involved in the DNA synthesis pathway. Inhibition of TS 
has been the major focus of chemotherapeutic targeting in colorectal cancer, as it is 
the main intracellular target of 5-fluorouracil, the main chemotherapy drug used in 
the treatment of colorectal cancer. The majority of studies looking at TS 
overexpression in colorectal cancer have found it to be an independent prognostic 
factor [Johnston PG et al., 1994; Edler D et al., 2000; Lenz HJ et al., 1998]. 
Unfortunately, intratumoral levels of TS within individual tumours have been found to
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be inconsistent, and in a subset of patients in whom multiple metastatic samples 
were taken, there was significant intra-patient heterogeneity of TS expression in the 
different metastatic sites [Aschele C et al., 1999]. Furthermore, in one recent large 
study, there was no association found between TS and survival in a group of Dukes’ 
B patients, and so further evaluation is probably needed [Allegra CJ et al., 2002].
There are clearly a host of genes involved in the cancer phenotype. Identification of 
some of these genes whose protein products are either up-regulated or mutated in a 
high proportion of colorectal tumours may improve the current understanding of the 
tumour biology, and in turn may allow them to be used as prognostic markers. For 
example, changes in the expression or activity of various growth factors and growth 
factor receptors may also contribute to the pathogenesis of colorectal cancer 
[Salomon DS et al., 1992; Tahara E, 1990]. Investigating the overexpression of such 
growth factor receptors may help to determine whether they provide independent 
prognostic information. Furthermore, characterization of these receptors may also 
provide alternative therapeutic strategies such as antibody therapy or small molecule 
inhibitors targeting the receptor, either alone or in conjunction with conventional 
chemotherapies.
1.6 Epidermal Growth Factor Receptor Family
The epidermal growth factor receptor (EGFR) family, also known as the erbB 
family, are a family of structurally related tyrosine kinase receptors, and comprises 
epidermal growth factor receptor (EGFR or HER-1), Human Epidermal Growth 
Factor Receptor-2 (HER-2), HER-3, and HER-4. These four proteins are widely 
expressed in epithelial, mesenchymal and neural tissues and play an important role
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during development [Gassman M et al., 1995; Siblia M and Wagner EF, 1995]. They 
are involved in the complex signal transduction cascade that regulates normal cell 
growth, differentiation, and survival of cells [Hung MC and Lau YK, 1999; Yarden Y 
and Sliwkowski MX, 2001].
Overexpression of EGFR is a common feature of human epithelial tumours, and 
has been reported in squamous cell carcinoma of the head and neck [Stanton P et 
al., 1994], oesophagus [Itakura Y et al., 1994], non-small-cell lung cancer [Rusch V 
et al., 1993], and endometrial adenocarcinoma [Khalifa MA et al., 1994]. 
Furthermore, its overexpression has been associated with a poor prognosis in 
patients with carcinoma of the lung, bladder, ovary and pancreas [Gullick WJ, 1991; 
Neal DE et al., 1990]. In colorectal cancer also it has been reported that 
overexpression of EGFR may indicate advanced stage of disease [Gross ME et al., 
1991] and may predict for metastatic potential [Radinsky R et al., 1995].
HER-2 is over-expressed to varying degrees in a number of human malignancies, 
including breast, ovary, bladder, prostate and stomach [Gullick WJ, 1990; Menard S 
et al., 2001]. HER-2 is a 185 kilodalton transmembrane glycoprotein, also designated 
p185HER'2, and is encoded by the c-erbB-2 gene, a proto-oncogene mapped to 
chromosome 17q21 [Coussens L et al., 1985]. HER-2 gene overexpression and/or 
amplification leads to continuous activation of HER-2 receptors, and is thought to 
play a pivotal role in transformation and tumourigenesis [Di Fiore PP et al., 1987; 
Hudziak RM et al., 1987].
The erbB receptors comprise three structural domains: an extracellular binding 
domain, a transmembrane domain, and a cytoplasmic tyrosine kinase domain. The
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EGFR family signaling is complex and involves a large number of ligands. EGFR is 
activated by seven ligands: epidermal growth factor (EGF), transforming growth 
factor a (TGF-a), amphiregulin, heparin-binding EGF-like growth factor, betacellulin, 
epiregulin and the novel member epigen [Strachan L et al., 2001]. HER-2 shares 
close (50-70%) structural homology with the EGFR. However, unlike EGFR, no 
ligands that directly bind to HER-2 protein have been identified. It is thought that 
HER-2 is trans-activated through heterodimerisation with other members of the 
epidermal growth factor family of growth receptors [Olayioye MA et al., 2000]. HER-3 
and HER-4 receptors bind heregulins, which are complex groups of proteins [Tzahar 
E et al., 1994; Pinkas-Kramarski R et al., 1997].
By binding to the extracellular domain of their respective receptors, the ligands 
induce receptor homodimers with the same receptor type (e.g. EGFR-EGFR), or 
heterodimers with a different receptor of the same family (e.g. HER-1-HER-2). 
Consequently, although HER-2 does not have a known ligand, this complex 
heterodimerisation between the various members of this family of cell surface 
receptors results in transactivation, with tyrosine phosphorylation of HER-2. HER-2 is 
thought to be the preferred dimerisation partner [Tzahar E et al., 1996]. Signaling 
through the EGFR family of receptors triggers a powerful network of down-stream 
cellular pathways, resulting in a range of responses including cell division, invasion, 
and cell death [Klapper LN et al., 2000; Yarden Y et al., 2001].
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1.7 Human Epidermal Growth Factor Receptor-2
1.7.1 Biological Significance
Various animal and in vitro studies strongly indicate that HER-2 plays an important 
role in oncogenic transformation, tumourigenesis, and metastasis [Benz CC et al., 
1993; Chazin VR et al., 1992; Hudziak RM et al., 1987]. Furthermore it has been 
shown that the growth of HER-2-positive human breast cancer cell lines and 
xenografts is inhibited by anti-HER-2 monoclonal antibodies [Harwerth IM et al., 
1993].
HER-2 has no known ligands, but is activated by transactivation following HER 
homo- and heterodimer combinations. Furthermore, those dimerizations that contain 
HER-2 are long-lived and transmit strong signals, and are thus associated with 
malignant growth [Rubin I and Yarden Y, 2001]. The reasons for this increased 
potency are thought to be two-fold. First, the heterodimers are characterised by 
relatively slower ligand dissociation [Alroy I and Yarden Y, 1997], and second, HER- 
2 is a slowly internalising receptor compared to EGFR whose ligand-induced 
endocytosis is rapid [Baulida J et al., 1996; Pinkas-Kramarski R et al., 1996]. Thus 
activation of the cell signal transduction pathway via HER-2-containing heterodimers 
results in an enhanced signal. Transmembrane activation of HER-2 results in 
intrinsic protein tyrosine kinase activation of the intracellular domain. Consequently, 
tyrosine autophosporylation of cytoplasmic signal proteins occurs and a cascade of 
different signalling pathways can be activated, transmitting signals across the 
cytoplasm to the nucleus. The complex system of heterodimerization of HER-2 gives 
a greater potential for diversification of the biologic messages and helps to explain 
how HER-2 plays a key role in oncogenic transformation in certain tumours.
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1.7.2 Indicators of increased HER-2 Production
Normal cells possess two copies of the HER-2 gene and have normal/low levels of 
HER-2 expression on the cell surface. HER-2 overexpression can occur through 
several different mechanisms:-
1. Gene amplification - multiple copies of the HER-2 gene are generated in the 
nucleus due to unknown dysregulation of DNA replication
2. Increased transcription of HER-2 gene(s). This can occur following amplification 
of the gene resulting in additional copies of HER-2, or by post-transcriptional up- 
regulation of the mRNA.
The elevated levels of HER-2 DNA and mRNA in turn can result in the 
overexpression of HER-2 on the cell surface.
The need to establish the HER-2 status of a tumour has been particularly important 
in breast cancers, where its prognostic role has been established. But, its level of 
overexpression has been investigated in many other human tumours which have 
also looked at the association between HER-2 and clinicopathological parameters. 
The most practical application of HER-2 testing would be the ability to predict the 
response to treatment and to guide treatment decision-making. With the availability 
of trastuzumab (Herceptin™), the first monoclonal antibody (mAb) approved for 
treatment of patients with metastatic breast cancer, the HER-2 status of tumours has 
gained increased therapeutic importance. However, even in breast cancer, a 
consensus regarding the optimum method for HER-2 detection in standard practice 
has not yet been achieved [Larsimont D et al., 2002].
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A number of different techniques exist to measure the level of HER-2 expression. 
These assays target different aspects of the HER-2 overexpression pathway: gene 
copy (fluorescence in situ hybridization [FISH] or polymerase chain reaction [PCR]), 
mRNA (PCR), cell surface protein (immunohistochemistry [IHC] or Enzyme-linked 
immunoadsorbent assay [ELISA]) and circulating receptor protein (ELISA). Each of 
these techniques has draw-backs.
Tissue-based detection of HER-2 overexpression by FISH and/or IHC has clear 
advantages over other techniques such as Western blot and PCR, which suffer from 
dilutional artefacts due to the mixture of normal and abnormal cells.
FISH is an assay that allows visualisation of HER-2 DNA in individual cells using a 
specific fluorescence-labelled probe. This assay can be used to look at gene 
amplification in individual tumour cells and this is one of its advantages.
The advantage of IHC and FISH is that they allow maintenance of the tissue 
architecture, and both can be carried out on formalin-fixed paraffin embedded 
tumour sections. IHC can additionally be performed on freshly frozen tissue. IHC and 
FISH assays both have their own level of diagnostic sensitivity and specificity. The 
FISH assay is said to be more convenient as it only requires small tissue samples. 
However, it is more time-consuming and costly, and necessitates particular expertise 
and equipment which may currently not be present in most histopathology 
departments [Jacobs TW, 2001 ;Jimenez RE et al., 2000].
Immunohistochemistry is the most frequently used assay to determine HER-2 
overexpression in tumour tissue. The advantages are that the technique is simple
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and cheap, and the tissue sample can be kept for reference, unlike the FISH assay 
which decays with time, leaving no permanent record. The disadvantage of IHC is 
that the reliability of the technique is dependent on a number of variables. 
Differences in the methodology used, fixation protocols, anti-HER-2 antibodies, and 
scoring systems can strongly influence the consistency and reproducibility of results 
[Press MF et al., 1994; van de Vijver MJ, 2001].
It is important to realise that the sequence of HER-2 gene amplification leading to 
increased HER-2 mRNA and protein overexpression is not necessarily linked 
causally or sequentially. For example, it has been shown that in a minority of breast 
tumours it is possible to have HER-2 overexpression in the absence of HER-2 gene 
amplification [Pauletti G et al., 1996]. It is precisely for this reason that in colorectal 
cancer, FISH may not be the most appropriate way of detecting HER-2 
overexpression. Although the level of HER-2 overexpression in colorectal cancer is 
quoted as 20-35% in the literature (and may be higher), gene amplification in 
colorectal cancer is a relatively rare event, since it has been observed in a low 
percentage (about 7%) of cases [D'Emilia J et al., 1989]. Under these 
circumstances, FISH would not be the ideal method of detection of HER-2 
overexpression in colorectal cancer, as it suggests that post-transcriptional up- 
regulation of the HER-2 gene may account for HER-2 overexpression in these 
tumours.
Furthermore, this discrepancy seen between IHC and FISH highlights a potential 
problem with using FISH to measure the level of overexpression of the receptor 
product of a gene. That is, gene overexpression does not necessarily translate into 
overexpression of the end protein product. It is possible for post-translational events
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to prevent full translation of the gene copies into a fully functional receptor [Anderson 
L and Seilhamer J, 1997]. In addition, It is the over-expressed HER-2, and not its 
gene, which is ideal for the selection of suitable patients for mAb-based therapy.
In the UK, the current laboratory practice for HER-2 testing in breast cancer 
recommends that HER-2 overexpression is by IHC with HercepTest™ (DAKO, 
Glostrup, Denmark), which is the only standardised, US Food and Drug 
Administration (FDA) -approved test for HER-2 evaluation [Jacobs TW et al., 1999]. 
FISH is only recommended in cases with moderate staining after HercepTest™ 
(score of 2+), to confirm the HER-2 status [Larsimont D et al., 2002].
1.7.3 The Prognostic Role of HER-2 in Human Cancers
HER-2 gene amplification and/or protein overexpression has been described in a 
variety of human tumours including carcinoma of the breast [Slamon DJ et al., 1987], 
ovary [Slamon DJ et al., 1989], endometrium [Hetzel DJ et al., 1992], stomach 
[Yonemura Y et al., 1991] and bladder [Coombs LM et al., 1991]. Although the 
clinical significance of HER-2 overexpression is uncertain in many human tumours, 
its prognostic role has been established in breast carcinoma.
In breast tumours, HER-2 overexpression is reported in 40-60% of intraductal 
carcinomas [van de Vijver MJ et al., 1988] and in 20-30% of invasive cancers 
[Gullick WJ, 1990; Menard S et al., 2001]. Studies have shown that a strong positive 
membranous HER-2 staining of the tumour is associated with an unfavourable 
prognosis in node-positive patients [Slamon DJ et al., 1987; Toikkanen S et al., 
1992], and, furthermore, HER-2-positive tumours may be less responsive to
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hormonal therapy [Newby JC et al., 1997]. This has led to the therapeutic use of anti- 
HER-2 monoclonal antibody therapy in breast cancer patients with metastatic 
disease, whose tumours are strongly HER-2 positive.
HER-2 overexpression has also been shown to be an independent prognostic 
indicator in gastric cancer [Yonemura Y et al., 1991]. However, studies looking at the 
prognostic utility of HER-2 overexpression in colorectal cancer have reached 
conflicting conclusions, and an overview of the current data is given below.
1.7.4 The Prognostic Role of HER-2 in Colorectal Cancer
Several studies have investigated the prognostic role of HER-2 in colorectal 
cancer, and these studies report different levels of HER-2 overexpression, and 
furthermore, the localisation of the immunostaining (i.e. membranous or 
cytoplasmic) varies. For example, moderate to strong membrane HER-2 expression 
in these studies ranged from 1.4% to 81.9% [Kakani V et al., 2002; McKay JA et al., 
2002]. In addition, while membrane HER-2 was associated with a poor prognosis in 
one study [Knosel T et al., 2002], others showed no such association [Benecke M et 
al., 2002; Chamberlain NL et al., 1999; Kakani V et al., 2002; McKay JA et al.,
2002]. Paradoxically, a further study found membrane HER-2 overexpression to be 
associated with a better prognosis in aneuploid tumours [Sun X-F et al., 1995].
Surprisingly, one study looking at HER-2 overexpression in Dukes’ B colorectal 
cancers, reported no evidence of membrane HER-2 overexpression in the 164 
tumours examined. However, 33.5% of the cases in this study showed cytoplasmic
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HER-2 immunostaining, and this was found to be an indicator of poor clinical 
outcome in Dukes’ B cancers [Kay EW et al., 1994b].
McKay et al performed a semi-quantitative assessment of HER-2 overexpression, 
according to the FDA-approved scoring system [Jacobs TW et al., 1999]. They found 
no significant association between clinical outcome and positive membrane HER-2 in 
249 colorectal tumours [McKay JA et al., 2002]. However, the FDA-approved scoring 
system makes no provision for cytoplasmic HER-2 assessment, and so its incidence 
in this study is not reported. Although membrane HER-2 alone has been shown to be 
of prognostic value in breast cancer, this may not be the only important criterion for 
assessing HER-2 overexpression in other tumours. There have been studies in 
breast [Zschiesche W et al., 1994] and thyroid cancer [Sugg SL et al., 1998] which 
have shown an association between good prognostic tumours and cytoplasmic HER- 
2.
Kapitanovic et al reported mixed cytoplasmic and membrane HER-2 
immunostaining in their cohort of colorectal cancers, and found that those cases with 
moderate or strongly positive tumours had a significantly poorer survival than those 
with weakly positive tumours [Kapitanovic S et al., 1997]. In contrast, Chamberlain et 
al found no association between cytoplasmic or membrane HER-2, and survival in 
96 tumours from an Australian cohort of patients [Chamberlain NL et al., 1999].
In colorectal cancers, the precise significance of membranous or cytoplasmic HER- 
2 immunostaining has yet to be fully elucidated. Current studies have yielded 
conflicting results as outlined above. A few investigators have suggested that 
cytoplasmic HER-2 overexpression is significant and may bear a correlation with
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survival, but this is still controversial. The current study will help to define the 
potential prognostic role, if any, of HER-2 (whether cytoplasmic or membranous) in 
localised colorectal cancer.
1.8 Microvessel Density and Human Cancers
Angiogenesis, the formation of new vessels from pre-existing ones, is an essential 
normal process in embryogenesis, menstruation and wound healing. However, 
aberrant angiogenesis is an integral part of tumour growth, invasion, and ultimately 
metastatic spread of cancers [Folkman J, 1990]. In the absence of angiogenesis, the 
tumour enters a dormant phase, whereby the rate of cell proliferation is balanced by 
apoptosis. It is widely believed that this dormant phase forms a significant part of a 
tumour’s lifespan. During this early period of tumour growth, the cancerous cells 
derive their oxygen and nutrition through processes such as simple diffusion. Beyond 
a certain size (1-2 mm), however, diffusion is no longer adequate and angiogenesis 
is needed for a number of reasons [Folkman J, 1990]. Firstly, neovascularisation 
provides the infrastructure to transport oxygen and other nutrients to the tumour for 
growth. Secondly, the formation and growth of microvessels within, and beyond the 
tumour into the surrounding tissues, provides the means of metastatic spread 
[Weidner N et al., 1991]. Finally, angiogenesis may also work through the paracrine 
effects of endothelial cells, with the release of growth factors that stimulate tumour 
growth and new blood vessel formation [Folkman J, 1994].
Several reports have demonstrated that colorectal cancers and other cancers 
produce a number of different angiogenic growth factors. Vascular endothelial 
growth factor (VEGF), also known as vascular permeability factor, seems to be one
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of the major factors responsible for tumour angiogenesis in many cancers [Claffey 
KP and Robinson GF, 1996; Zhang HT et al., 1995]. VEGF is a 34-42 kDa 
multifunctional glycosylated dimeric protein, and is expressed in 4 isoforms derived 
by alternative mRNA splicing [Houck KA et al., 1991; Tischer E et al., 1991]. It binds 
to specific receptors, namely VEGF-receptor 1 (flt-1) and VEGF-receptor 2 (flk- 
1/kdr), which are tyrosine kinase receptors expressed on endothelial cells [Ferrara N 
and Davis-Smyth T, 1997]. VEGF expression can be determined by the analysis of 
mRNA levels or by immunohistochemistry with anti-VEGF antibodies, in fresh or 
paraffin-embedded tumour sections [Vermeulen PB et al., 1996]. However, other 
angiogenic factors have also been implicated, and these include basic fibroblast 
growth factor, platelet-derived growth factor (PDGF), angiogenin, and thymidine 
phosphorylase [Papamichael D, 2001].
The mechanism whereby some tumours remain locally invasive for long periods 
whereas others, of similar size, metastasize early is still not fully understood. 
However, it is clear that there is a well demarcated transformation from the pre- 
angiogenic phase of a tumour to the angiogenic phase. The pre-vascular phase is 
usually associated with limited tumour growth and a low probability of developing 
metastases. In the vascular phase, there is a clear transformation in the biological 
behaviour of the tumour with rapid growth, possible bleeding, and the potential for 
metastasis. This is well illustrated in studies looking at cancers of the cervix [Sillman 
F et al., 1981] and breast [Brem SS et al., 1977], and cutaneous melanoma 
[Srivastava A et al., 1988; Herlyn M et al., 1987;].
The first evidence that tumour vascularity could predict for the development of 
metastases was reported in cutaneous melanoma [Srivastava A et al., 1988]. Since
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then, a number of studies in breast cancer have shown that a quantitative estimation 
of microvessel density (MVD) can be shown to be associated with a poor prognosis 
in both node positive and node negative disease [Weidner N et al., 1992; 
Giatromanolaki A et al., 1999]. MVD has also been shown to be of prognostic 
significance in non-small cell lung cancer [Macchiarini P et al., 1992], and stomach 
[Tanigawa N et al., 1996] and prostate [Weidner N et al., 1993] cancers.
Many of the quantitative studies investigating the prognostic role of MVD in 
tumours have been conducted by marking endothelial cells with specific antibodies, 
using immunohistochemical staining methods. In these studies, tumour 
vascularization, assessed by counting vessels immunostained for Factor Vlll-related 
antigen (F8RA, also known as von Willebrand factor) or endothelial cells, CD31 or 
CD34, was correlated with the incidence of metastases and/or survival [Takebayashi 
Y et al., 1996; Tanigawa N et al., 1997; Vermeulen PB et al., 1999].
1.8.1 Microvessel Density and Colorectal Cancer
Over the last decade, a number of studies have attempted to investigate the 
potential prognostic role of angiogenesis in colorectal cancer, using various 
angiogenic markers as described above.
Although there have been a number of studies which have used anti-F8RA mAbs 
to quantitatively assess tumour vascularity, increasingly anti-CD31 and anti-CD34 
mAbs are being utilised because of the increased specificity of the latter antibodies 
for endothelial cells when using paraffin sections [Vermeulen PB et al., 1996; 
Tanigawa N et al., 1996]. The adverse impact of tumour angiogenesis in colorectal
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cancer in terms of relapse or prognosis has been investigated using one or more of 
these factors. These previous studies have however reached conflicting conclusions.
Four of these studies showed a significant association between microvessel count 
and survival [Choi HJ et al., 1998; Takebayashi Y et al., 1996; Tanigawa N et al., 
1997; Vermeulen PB et al., 1999]. Although two other studies also showed an 
association between vessel counts and survival, this was only on univariate analysis 
[Frank R et al., 1995; Saclarides TJ et al., 1994].
Saclarides et al did not show any association between MVD and metastases. In 
this small series of only 48 patients with rectal cancer, they found significantly higher 
angiogenesis scores (mean±SD) in patients who died before five years (18.4 ± 5.2), 
compared to the MVD in tumours of survivors at this same time interval (14.7 ± 5.3) 
[Saclarides TJ et al., 1994]. Frank et al. had similar results with significantly higher 
angiogenesis scores for patients with recurrent disease, and there was also a better 
survival seen in patients with a MVD of less than 28. Another large study which 
evaluated 133 colorectal tumours (stages Dukes’ A-D), found a significant 
association between MVD and overall survival, and the tumour vessel count was 
also the most important prognostic factor [Tanigawa N et al., 1997].
Takahashi et al demonstrated that VEGF expression in Dukes B (i.e. node 
negative) colon cancers was significantly associated with time to recurrence. 
However, but there was no association with survival, and only 27 patients were 
included in this study [Takahashi Y et al., 1997].
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MVD has also been demonstrated prospectively to be an independent prognostic 
factor in 116 Dukes’ A-C colorectal cancers, using the JC-70 anti-CD31 mAb 
[Vermeulen PB et al., 1999]. No such association was found in the Dukes’ D 
patients, and there was also no correlation between MVD and the presence of lymph 
node metastases detected at surgery. In another series of 133 patients, there was 
again a very strong association between MVD and both haematogenous spread of 
disease and survival [Tanigawa N et al., 1997]. In this study, MVD was not 
associated with lymph node or peritoneal metastases, suggesting a different 
mechanism in the development of these metastases.
Choi et al looked at the level of angiogenesis in 127 colorectal cancer specimens, 
using F8RA. They found a significant association between high MVD and liver 
metastases (p=0.0004), and MVD was also associated with many of the 
conventional pathological variables, such as histologic grade, lymphatic and vascular 
invasion, and Dukes’ stage. On multivariate analysis, MVD was found to be an 
independent prognostic marker (p=0.0004). They concluded that MVD, as measured 
by F8RA immunostaining, did reflect the biological malignant potential of colorectal 
cancers [Choi HJ et al., 1998].
There were also two negative studies which did not show MVD to have any 
prognostic role in colorectal cancer [Cianchi F et al., 2002;Pietra N et al., 2000]. In 
one of these studies, looking at node-negative patients, the investigators found a 
significant association between high MVD and lymphocytic infiltration of the tumour 
[Cianchi F et al., 2002]. The presence of conspicuous lymphocytic infiltration in a 
tumour is considered to be an effective cell-mediated immune response against the 
tumour, and has been deemed a favourable pathological factor, and therefore may
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have interfered with its predictive value. Nonetheless, a large study looking at 212 
patients showed a completely opposite result from that previously reported. They 
demonstrated, on univariate analysis, a significantly longer survival in those patients 
whose tumours had a higher MVD [Lindmark G et al., 1996],
1.9 Molecular Targeting in Cancer
Tumour growth, invasion and progression to metastasis is a complex process 
which involves angiogenesis, and the induction of various growth factors such as the 
family of epidermal growth factors and vascular epidermal growth factors, and other 
stimulators of this process [Fox SB et al., 2001]. In the quest to improve the overall 
survival of colorectal cancer patients after radical surgery, there has been a recent 
significant focus on the development of agents which target the numerous pathways 
involved in tumour angiogenesis, invasion and metastasis.
1.9.1 Signal Transduction Pathways
The EGFR pathway is aberrant in up to 75% of colorectal cancers [Nicum S et al.,
2003]. Thus, agents that target the extracellular ligand-binding regions and the 
intracellular tyrosine kinase domain have been investigated to try and abrogate the 
mitogenic signals mediated by this receptor. Cetuximab, a selective anti- EGFR 
mAb, has been shown to produce significant activity in combination with Irinotecan 
chemotherapy, in patients whose colorectal cancers were previously refractory to 
Irinotecan-based chemotherapy [Saltz L et al., 2001]. Cetuximab has now been 
approved by the US Food and Drug Administration for the treatment of metastatic
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colorectal cancer in combination with chemotherapy (February 2004), and has 
entered phase III trials both in the adjuvant and metastatic setting in the UK.
Three very closely related proteins in the ras family, H-ras, K-rasB and N-ras, are 
primary regulators of cell growth. Mutations in the k-ras protein are found in about 
50% of colorectal tumours and are believed to play an important part in 
tumourigenesis [Breivik J et al., 1994]. A wide variety of growth factors result in a 
rapid and transient elevation of active GTP-bound ras proteins. These include EGF 
and PDGF [Soler C et al., 1994]. Thus it seems that ras proteins are essential 
components of the tyrosine-mediated mitogenic signaling pathways.
Post-translational modification of the ras proteins is essential for its effective 
functioning, and the enzyme farnesyl protein transferase (FPTase) plays an 
important part in this process. Oncogenic ras proteins lose their transforming ability 
when farnesylation is prevented. Thus FPTase inhibitors have been investigated in 
metastatic colorectal cancer patients who have failed conventional chemotherapy. 
Unfortunately, the results so far have been disappointing [Verslype C et al., 2001].
1.9.2 Immunotherapy
In the adjuvant setting, a study looking at the effect of a monoclonal antibody 17-1 A, 
that binds a tumour-specific antigen, in Dukes’ C patients reported no advantage 
from the addition of 17-1A [Gambill BD, 2001].
Other methods of targeting tumour-associated antigens have included vaccination 
against carcinoembryonic antigen (CEA), an oncofetal antigen expressed in about
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85% of patients with colorectal cancer. Trials are currently on-going in the adjuvant 
setting, as phase I trials have not demonstrated any significant toxicity [Cole DJ et 
al., 1996].
Antibody directed enzyme prodrug therapy (ADEPT) is another form of targeted 
therapy in which a prodrug is selectively activated at the tumour site via an enzyme 
which is conjugated to an antibody, targeted to the specific tumour. Initial trials have 
shown evidence of tumour response, and further studies are on-going [Francis RJ et 
al., 2002].
1.9.3 Anti-Angiogenesis Therapy
The ultimate target of anti-angiogenic therapy is the tumour blood vessel. They are 
attractive as therapeutic targets because they express proteins not expressed on 
normal blood vessels. Bevacizumab (BV), a humanized mAb that targets and binds 
VEGF, has been shown to prolong survival in a phase II clinical trial of colorectal 
cancer [Kabbinavar F et al., 2003]. This would seem to establish the validity of the 
anti-angiogenic approach in colorectal cancer. However, there is no evidence to 
suggest that tumour VEGF expression is predictive of clinical response.
Furthermore, a consensus on the method of assessing tumour neoangiogenesis has 
yet to be agreed widely.
1.9.4 Cyclo-Oxygenase Type 2 (Cox 2) Pathway
Non-steroidal anti-inflammatory drugs (NSAIDs), such as sulindac, have been 
shown to have an anti-tumour effect, thought to be mediated through the COX 2
Page 39
Chapter one Introduction
pathway [Gasparini G et al., 2003]. The COX 1 pathway is responsible for the 
gastrointestinal side-effects of this class of drugs. Selective COX 2 inhibitors have 
also been shown to inhibit angiogenesis and induce apoptosis in colorectal cancer 
cells [Elder DJ et al., 1997]. The selective COX 2 inhibitor, Rofecoxib is currently 
being assessed as an adjuvant treatment in a phase III double-blinded placebo- 
controlled trial in colorectal cancer patients. The aim of the study is to see if 
Rofecoxib, given for 2 or 5 years, improves the relapse-free and overall survival in 
Dukes’ C colorectal cancer patients following completion of their conventional 
adjuvant treatments (i.e. chemotherapy and/or radiotherapy).
1.10 Aims of the Study
The aim of adjuvant chemotherapy in colorectal cancer is primarily to improve 
overall survival. Currently the selection of patients for whom chemotherapy offers a 
survival advantage is mainly determined by the presence of regional nodal 
metastases in the histological specimen (i.e. Dukes’ stage). There is a need for 
better prognostic markers to enable selection of a poor prognostic group, and to 
avoid the over-treatment of a large number of patients.
HER-2 has been shown to be a significant prognostic marker in breast cancer, and 
may also predict response to therapy. It has therefore been used in breast cancer to 
tailor adjuvant therapy.
In colorectal cancer, a number of studies have investigated the role of HER-2 and 
microvessel density as prognostic markers, but they have had conflicting results. In 
view of the controversies, the aim was to investigate the expression and prognostic
Page 40
Chapter one Introduction
significance of these two parameters in patients with colorectal cancer, and their 
association with clinico-pathological factors.
Chapter two Materials and Methods
Chapter Two 
Materials and Methods
2.1 Human Tumour Cell Lines
A panel of human colorectal, breast, and head and neck tumour cell lines were used 
in this study. Of these, the human colorectal tumour cell lines CCL218 (HT29), 
CCL225, CCL228, CCL244 were obtained from the American Tissue Culture 
Collection (ATCC), Massas, USA. The human colorectal cell line DiFi was a gift to Dr 
Helmout Modjtahedi from Dr Zhen Fan at the MD Anderson Cancer Centre, Houston, 
USA.
The following cell lines were used as controls in this study: Human breast (SKBR3) 
and ovarian (SKOV3) cancer cell lines that express high levels of HER-2, a head and 
neck (HN5) cell line which expresses high levels of EGFR, and a breast carcinoma 
(MCF-7) cell line that expresses low levels of EGFR and HER-2 [Cowley G et al., 
1984; Modjtahedi H et al., 1998; Boente MP et al., 1998; Lewis GD et al., 1993; 
Modjtahedi H et al., 1993a].
2.2 Cell Culture
2.2.1 Culture Media and Foetal Calf Serum
Dulbecco’s Modified Eagles medium (DMEM) and Penicillin-Streptomycin-Neomycin 
solution (100x) were obtained from Sigma- Aldrich Co. Ltd, Dorset, Uk. Foetal Calf 
Serum (FCS) was obtained from the PAA Laboratories Ltd (Somerset) and was heat 
inactivated at 56°C for 50 minutes before use. All the human tumour cell lines were
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cultured routinely in DMEM supplemented with 10% FCS, penicillin (50units per ml_), 
streptomycin (50|xg/mL) and neomycin 100|xg/mL), as described previously 
[Modjtahedi H et al., 1998]. All cultures were incubated at 37°C in an atmosphere of 
5% C02. Depending on the quantity of the cells required, they were cultured in large 
(175cm2), medium (75cm2) or small (25cm2) flasks.
2.2.2 Passaging and Growth of Tumour Cell Lines
Cells were cultured in 20-25 mL DMEM/10%FCS in 75cm2 flasks, as described 
above. Once confluent, the cells were passaged weekly by first discarding the old 
medium. They were then incubated with 0.02% trypsin in phosphate-buffered saline 
(PBS), containing 0.04% Na2EDTA, for 3-5 minutes, at 37°C. This trypsinisation time 
was variable depending on the cell line used, and sometimes needed extension of 
the incubation time, and/or an increase in the trypsin concentration (e.g. HN5 cells).
Once the cells were suspended, the trypsin was inactivated by the addition of 1.0 
mL of FCS. The cell suspension was then pelleted by centrifugation for 3 minutes, at 
1600-1800 rev/min. The cells were then re-suspended in fresh DMEM/10%FCS in a 
culture flask, and all cultures were incubated at 37°C, in an atmosphere of 5%C02. 
For growth inhibition assays, in order to reduce the effect of endogenous growth 
factors present in the FCS, the concentration of FCS was reduced to 2%.
2.2.3 Long Term Storage of Cells
Samples of human tumour cell lines were stored at -135°C in liquid nitrogen. Sub­
confluent cells were trypsinised and centrifuged into a pellet as described above.
Page 43
Chapter two Materials and Methods
After discarding the supernatant, the cells were re-suspended in freezing medium, 
which constituted 93% of FCS mixed with 7% dimethyl-sulphoxide (DMSO). One 
millilitre aliquots of cells were then transferred to 1.5 mL freezing vials (Nunc, Gibco 
Europe Ltd), which were then frozen initially at -80°C for 24 hours, and then 
transferred to liquid nitrogen for long term storage.
When the cells were required again, the particular vial was removed from the liquid 
nitrogen, and thawed quickly at 37°C. The cells were then re-suspended gently, and 
diluted, in 20 mL of DMEM/10%FCS. After centrifugation, the cells were washed 
once more with 20 mL of fresh medium, and then plated into a 75 cm2flask.
2.3 Antibodies
The rat mAb ICR12 (lgG2a) was raised against the external domain of HER-2 using 
the human breast carcinoma BT474 as the source immunogen. This antibody was a 
kind gift from the late Dr Christopher Dean (The Institute of Cancer Research, 
Sutton, UK) to Dr Helmout Modjtahedi [Dean C et al., 1993;Styles JM et al., 1990]. 
The rat mAb HM64.13 (lgG2b) was raised against the external domain of HER-2 on 
the human breast carcinoma cell line SKBR3 by Dr Helmout Modjtahedi.
To assess microvessel density, the anti-CD31 monoclonal antibody (JC70) was 
obtained from DAKO (Glostrup, Denmark). The rat mAbs ICR16 and ICR62 are 
directed against the external domain of the EGFR and were produced and 
characterised as described previously [Modjtahedi H et al., 1993b; Modjtahedi H et 
al., 2003].
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The goat anti-rat IgG polyclonal antibody (Star 71), for use in radioimmunoassay, 
and the biotinylated rabbit anti-rat immunoglobulin, for use in the 
immunohistochemistry, were purchased from Serotec Ltd., (Oxford, UK) and DAKO 
respectively. For use in the radioimmunoassay, the Star 71 was also labelled with 
Iodine-125 to a specific activity of 10piCi/pig using the lodogen procedure, as 
described previously [Modjtahedi H et al., 1993b]. The goat anti-rat IgG conjugated 
to Fluorescein Isothiocyanate isomer (FITC) (Star 69), for use in the fluorescence- 
activated cell sorter (FACS) analysis was obtained from Serotec Ltd., (UK).
Biotinylated goat anti-mouse and anti-rabbit secondary antibody was used in the 
CD31 immunohistochemistry procedure, and this was purchased from DAKO.
2.4 Other Chemical Reagents
The CD31 immunostaining was performed using the reagents recommended by the 
automated system, Dako TechMate™ 500 Plus. These were all ChemMate™ 
products (DAKO) and included the antibody diluent, the ‘negative control’ reagent, 
and the Washing Buffers 1-3, and Water Wash.
The EGFR tyrosine kinase inhibitor (TKI), gefitinib, was a gift from AstraZeneca to 
Dr H Modjtahedi.
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2.5 Immunoprecipitation of 35S-Methionine-labelled Proteins
Specific cellular proteins were isolated from radiolabelled cell extracts, by 
precipitation with antibody, and analysed by electrophoresis in polyacrylamide gels 
containing sodium dodecyl-sulphate (SDS). SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) is a technique which is routinely used to determine the molecular 
weight of a particular protein. Because the migration of the protein is determined by 
its molecular weight, shape and electrical charge, the electrophoretic mobility of a 
particular protein through the polyacrylamide gel will be inversely proportional to its 
molecular weight. By using a standard marker of known molecular weight, it is 
therefore possible to determine the molecular weight of the target protein.
2.5.1 Preparation of Radiolabelled Cell Lysate
The human breast carcinoma cell line SKBR3, overexpressing the HER-2 antigen, 
were grown in 10% DMEM in large (175 cm2) flask until they were sub-confluent. The 
cells were then washed once with 10mLs of Methionine-Cysteine free DMEM 
(Sigma) containing 10% FCS, and the medium then discarded. The cells in each 
flask were then incubated, at 37°C, with 10 mL of the same medium for 1 hour, prior 
to overnight incubation at 37°C in the presence of 500pCi of Tran35S-Label™ (ICN).
After radiolabelling of the cells, the cell lysate was then prepared by adding 10 mL of 
lysing buffer (PBS azide containing 1% Triton X-100 and 1mM PMSF) for 30 minutes 
at 4°C. The cell lysate was then transferred to Ultra-Clear centrifuge tubes 
(Beckman) and centrifuged at 30,000 r/m for 30 minutes in a UltraCentrifuge
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(Beckman). The cell lysate was then collected and either stored at -80°C or used in 
the immunoprecipitation study (see section 2.5.3).
2.5.2 Preparation of Immunoadsorbent Beads
Immunoadsorbent beads were prepared by linking the anti-HER-2 antibody to 
activated Protein G Sepharose 4 Fast Flow at a concentration of 5pg of each mAb 
per 100pl of Protein G (Amersham Pharmacia Biotech). Briefly, 400pl of Protein G 
was mixed with 80pl of each primary antibody (80pg) or 80pl of PBS (control) in 
1.5mL eppendorf tube and the total volume of each tube was adjusted to 1mL using 
0.5% PBS azide. Following overnight incubation on a rotator at 4°C, the 
immunoadsorbed beads were then centrifuged at 500 rpm for 1 min and the 
supernatant discarded. After three washes with 1mL 0.5% PBSA, the 
immunoadsorbent beads were re-suspended in 0.5% PBS-azide washing buffer for 
use in immunoprecipitation study.
2.5.3 Immunoprecipitation
Immunoprecipitates were prepared by incubating 1 mL aliquots of radiolabelled cell 
extract with 100 pi of antibody-linked beads in an eppendorf for 2 hours at room 
temperature. Each tube was then centrifuged at 500rpm for 1 min, the supernatant 
was discarded. The immunoprecipitates in each tube were then washed four times 
with 500 pL of PBS azide and then mixed with equal volume of SDS-sample buffer 
(section 2.5.4), heated at 95°C for 5 minutes. 50 pL aliquots of the sample were 
then loaded carefully into the individual wells of the SDS gel. The molecular weight
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standard (MultiMark™), which is pre-reduced, was loaded into the first well for 
reference.
2.5.4 Materials for SDS-PAGE
Molecular Weight Marker:
Tricine MultiMark™ Multi-coloured Standard (Invitrogen LifeTech).
Acrylamide Stock Solution
30% Acrylamide (37.5:1) Bisacrylamide solution was obtained from Northumbria 
Biological Ltd. (UK).
Sample Buffer (reducing condition):
Stacking buffer 50 mL
SDS 4 g
Dithiotheritol 2 g
Glycerol 10 mL
PMSF (0.4M in ethanol) 5 mL 
H20: 35 mL
Bromophenol blue: trace
Resolving Buffer pH 8.8: 
Trizmabase 181.6g
SDS 4.0 g
Add de-ionized water to 1 L
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Adjust with HCL to pH 8.8
Stacking Gel Buffer pH 6.8:
Trizmabase 15.5 g
SDS 1.0 g
Add H20 to 500 mL
Adjust with HCL to pH 6.8
Running Buffer 10X Stock:
Trizmabase 270g
Glycine 1285.5g
SDS 89.3g
H20 to 9000 mL
With the exception of sample buffers, which were stored frozen at -20°C, all other 
buffers were stored at -4°C.
2.5.5 Casting the SDS Gel
The SDS-page was formed using the method described by LaemmLi (1970) using 
the BRL Vertical Gel Electrophoresis System V-16-2 (BRL, Paisley, Scotland). 
Before setting the gels, the glass plates, spacers and sample combs were washed 
thoroughly in distilled water and dried. The BRL system was then fitted together 
ensuring that a water-tight seal was achieved between paired glass plates.
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The appropriate volume of a 7.5% resolving gel was then made using the required 
concentration of polyacrylamide according to the values listed in Table 2.1. The 
acrylamide gel was then poured into the gap between the glass plates, leaving 
sufficient space for the stacking gel. A thin layer of water was then laid over the 
resolving gel using a Pasteur pipette to prevent diffusion of oxygen into the gel and 
inhibition of polymerisation, and also to obtain a flat surface for the polymerised gel.
After polymerisation was complete (30-60 minutes), the thin water layer was 
removed, using a Pasteur pipette. A 4.5% Stacking gel solution was made according 
to the values in Table 2.5, and this was then quickly poured onto the polymerised 
resolving gel. The plastic comb delineating the wells was inserted into the stacking 
gel at this stage. The SDS-page was then left to set overnight, at 4°C.
2.5.6 Electrophoresis and Autoradiography
Each sample was analysed by 7.5% SDS-Polyacrylamide Gel Electrophoresis. 
Electrophoresis was carried out, in the running buffer, at a constant current of 
30mA/gel. The electrophoresis was stopped when the bromophenol blue marker was 
about 1 cm from the bottom of the gel.
In order to analyse the immunoprecipitated proteins labelled with 35S-methionine, 
the gel needed to be dried. This is because 35S emits low energy p-particles, which 
are attenuated within a few millimetres of their source.
The gel was therefore fixed in 10% acetic acid for 1 hour, and then immersed, with 
gentle agitation, for 30 minutes in a fluorographic reagent, ‘Amplify’ (Amersham).
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Table 2.1 Preparation of Resolving and Stacking Gels for SDS- 
PAGE
GEL TYPE: RESOLVING STACKING
ACRYLAMIDE (%) 7.5 4.5
Acrylamide Stock3 (mL) 10.0 2.8
Resolving Buffer (mL) 10.0 -
Stacking Buffer (mL) - 9.6
Water (mL) 19.6 7.6
Ammonium 0.4
Persulphate13 (mL)
TEMEDC (piL) 16.0 16.0
TOTAL VOLUME (mL) 40.0 20.6
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The gel was then transferred to filter paper, of appropriate-size, and dried under 
vacuum on a heated-bed gel dryer for 2 hours. After drying, the gel was exposed to 
Fuji RXfilm (Fuji Ltd., UK) within a light-proof metal cassette, at -70°C.
The autoradiograph was developed in Kodak developer for 10-30 seconds until the 
bands were clear, rinsed in water for 10 seconds, and then fixed in fixative solution 
for 20 seconds, before washing in tap water again, and then leaving to dry at 37°C.
2.6 Radioimmunoassay
The expression of HER-2 and EGFR on tumour cell lines was determined using 
radioimmunoassay, as described previously [Modjtahedi H et al., 1993b;Modjtahedi 
H et al., 1997;Styles JM et al., 1990]. Briefly, human tumour cell lines were grown to 
confluence in 200fxl of DMEM containing 10%FCS in a 96-well plate. The cells were 
plated so as to have approximately the same number of cells seeded in each well at 
confluence. Following three washes of confluent cells with DMEM/2%FCS, triplicate 
50 pil samples of each mAb (150 nM) in 2% DMEM, or medium alone, was added to 
the confluent monolayer of tumour cells and the plates were incubated for one hour 
on ice. Following three washes with 2% FCS/DMEM, the bound activity was 
measured by the addition of 125l-Star 71 (105 cpm/well) for 1 hour on ice. Following 
three more washes with 2% FCS/DMEM, the cells in each well were lysed by 
addition of 150 i^l per well of 1M NaOH containing 1% Sarkosyl. The lysate was 
transferred to LP22 tubes (Elkay, Basingstoke, Hants) and the radioactivity present 
was determined in a LKB-WALLAC Clinigamma-1272 counter (Finland).
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2.7 FACS Analysis
FACS analysis is a method used to measure cell surface levels of specific proteins, 
and was carried out as follows.
The human tumour cell lines were grown to near confluence in 75cm2 culture flask. 
Following trypsinisation, the cells were counted and then re-suspended at 106 cells 
per mL of DMEM/2%FCS. Then 1mL of each cell line was mixed with 10pg of each 
mAb (stock 1mg/mL) in a 1.5mL eppendorf tube, by rotation at 4°C for 1 hour. 
Control cells were treated with 10pl of medium alone. The cells were then washed 
twice before incubation with the secondary antibody. After each wash, the cells were 
centrifuged at 1800 rpm for 5 minutes and the supernatants were discarded. At the 
end of the second wash, the cells were re-suspended in 1mL of DMEM/2%FCS 
containing FITC F(ab’)2 fragment of goat anti-rat IgG (Star 69), and mixed on a 
rotator 4°C for 1 hour. Following three washes with DMEM/2%FCS to remove any 
unbound fluorochrome, the final pellet of cells were re-suspended in 2 mL of 
FACSFlow (Becton Dickinson) and analysed using a FACScan cell sorter (Becton 
Dickinson).
2.8 Growth Inhibition Studies in vitro
The effect of antibodies on the growth of human tumour cells, in vitro, was 
determined using the method described previously [Modjtahedi H et al., 1993b]. 
About 5 X 103 cells in 100 pL of 2% DMEM were seeded into each well of a 96-well 
plate. Following incubation for 4 hours at 37°C, 100 \iL aliquots of each mAb 
(300nM), gefitinib (4 |aM) were added to the wells in triplicate. Controls were set up
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with wells that contained medium alone. The cultures were then incubated for about 
a further 5 days, until the cells incubated in medium alone were almost confluent. All 
the cells were then fixed by adding 20 pJ of 0.25% glutaraldehyde (Sigma) to each 
well for 20 minutes, washed in water and then air dried. The cells were then stained 
by adding 100 pi of 0.05% methylene blue to each well for 15 minutes. After washing 
with tap water and air drying, 200 pi of 0.33N hydrochloric acid was added to each 
well, gently mixed and the absorbance was measured at 620nm (A62o) using the 
Labsystem Multiskan RC (Finland).
2.9 Patient Information
One hundred and seventy consecutive patients with Dukes’ B and C colorectal 
cancers who underwent radical surgery at the Royal Surrey County Hospital 
(Guildford, UK) between January 1990 and December 1998 were included in this 
retrospective study. Ethical approval for the study was given by the ethics committee 
at the Royal Surrey County Hospital. The names of two hundred and ten patients 
with a history of Dukes’ B or C colorectal cancer were initially obtained from the 
GUTS (Guildford Undetected Tumour Screening) database. Unfortunately, the 
information on the database for these patients was inadequate, and often 
incomplete, for the purposes of this study. Therefore, the clinical and pathological 
information for all 210 patients had to be obtained by reviewing their hospital notes 
(manually), and their histopathology reports. Therefore, a significant amount of time 
was consumed by tracking, collecting, and reviewing all 210 patient notes, so as to 
have accurate clinico-pathological, and follow-up details for each patient.
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Forty patients were eventually excluded from the study for various reasons. These 
included no follow-up data (n=9), mis-diagnosis on the database (e.g. in fact a 
Dukes’ A cancer) (n=2), and incomplete histology (n=6). Any patient who had an 
incomplete excision on histopathological review was also excluded (n=2). Other 
reasons for patient exclusion included repeated poor immunohistochemistry (n=2) on 
the patient’s tumour section, and an inability to find the tumour block (n=17). Patients 
who died within 30 days after surgery were excluded from this study to exclude bias 
(peri-operative death), as were those who had a second malignancy (n=2).
Detailed clinicopathological information was available for each patient. This included 
the tumour size, grade, presence of lymphovascular invasion, and the Dukes’ stage. 
For the Dukes’ C cases, the number of nodes involved by metastatic disease, and 
the involvement of the apical node was also documented. Information such as 
whether the patient had received radiotherapy or chemotherapy post-operatively was 
also obtained. None of the patients had received radiotherapy or chemotherapy 
before surgery.
Follow-up data was obtained by reviewing the patients’ notes, and in collaboration 
with the Thames Cancer Registry (London). In a few cases, the patient’s General 
Practitioner was contacted for follow-up information. Survival was measured from the 
date of the patients’ operation until death or the end of June 2002, whichever came 
first. For those patients with recurrent disease, the date and site of relapse was 
obtained, in addition to their last observation (or date of death).
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2.10 Immunohistochemistry
The main goal for the IHC technique in these studies was to achieve optimal 
specific immunostaining whilst also minimising interference from background 
staining. This optimisation process included the investigation of a series of mAbs, 
with varied dilutions and incubation times. It is well recognised that the epitope 
recognised by each antibody, incubation time and temperature, as well as antibody 
concentrations, are all tightly interwoven in their effect on the immunostaining. 
Inconsistent changes in these factors may cause significant variations in the intensity 
and overall quality of the immunostaining.
2.10.1 Optimisation of Immunostaining with mAb HM64.13
The optimisation of HM64.13 for use in immunohistochemical detection of HER-2 in 
paraffin embedded sections was performed as follows. Four human colorectal 
cancer specimens, which previously had been shown to be HER-2 positive, and a 
HER-2 overexpressing breast carcinoma cell line SKBR3 (positive control; see 
Section 2.10.2) were incubated with a 1:100, 1:200 and 1:500 dilutions of mAb 
HM64.13. The incubation period was also varied for each dilution, 30 minutes, 60 
minutes and overnight incubation. The intensity of immunostaining was then 
detected using a standard IHC procedure (section 2.10.3), and the percentage 
number of cells in the tumour section exhibiting positive membranous or cytoplasmic 
immunostaining was determined.
To ensure that the IHC process was standardised, and the results consistent, a 
subgroup of 20 paraffin-embedded colorectal tumour sections were immunostained
Page 56
Chapter two Materials and Methods
using HM64.13 monoclonal antibody. This IHC method (section 2.10.3) was used 
subsequently for HER-2 immunostaining of a larger cohort of colorectal cancer 
sections.
2.10.2 Preparation of SKBR3 Ceil Pellet for Immunostaining
The pellet for the human breast carcinoma cell line SKBR3 was prepared in the 
following way. Briefly, SKBR3 cells were grown in DMEM/10%FCS to near 
confluence in a large flask, as described above (section 2.2.2). The cells were then 
gently scraped off the flask and transferred (with medium) into a universal tube. 
Following centrifugation at 1600 rpm for 5 minutes, the supernatant was discarded. 
The pellet was then re-suspended in formalin for 45 minutes, and the cells fixed. The 
fixative was subsequently discarded after a further 5 minutes centrifugation. The 
cells were then washed twice in 5-10 mL of formaldehyde. After the final wash, and 
centrifugation, the formaldehyde was discarded, and the resultant pellet transferred 
to blotting paper. It was then embedded in paraffin wax, and after cooling, 3 |im 
sections were cut, and immunostained as below.
2.10.3 Immunostaining with mAb HM64.13
The overexpression of HER-2 in the tumour samples from 170 patients with Dukes’ 
B and C colorectal cancers were assessed using the anti-HER-2 mAb, HM64.13 and 
a standard avidin-biotin-horseradish peroxidase system. This followed an initial 
standardisation process, as described above (section 2.10.1), to ensure 
reproducibility of the immunohistochemical staining.
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Formalin-fixed paraffin-embedded tumour sections (3 pm) were cut from the blocks 
used for histopathological diagnosis, and mounted on slides. A particular tumour 
block was chosen, and the section of tumour initially stained with eosin and 
haematoxylin, to ensure that the cancer section was representative of the tumour. 
The tumour sections were initially dewaxed by placing the mounted slides in a slide 
rack, and immersing them in 2 separate xylene baths for 5 minutes each. The slides 
were then rehydrated by washing them for 1 minute, in each of three changes of 
industrial methylated spirit (IMS). No antigen retrieval was required. Endogenous 
peroxidase activity was blocked with a 3% hydrogen peroxidase solution for 5 
minutes, followed by washing in distilled water, and then in Tris-buffered saline 
(TBS). Non-specific background staining, from secondary antibody binding, was 
blocked by applying 200 pL of normal rabbit serum (dilution 1:5) to each slide in a 
humidity chamber for 30 minutes. After blotting the excess rabbit serum, each 
tumour section was then incubated for 30 minutes with 200pl of the primary mAb, 
HM64.13, at optimal dilution (5pg/mL), and at room temperature. At the end of this 
incubation period, the slides were washed in TBS for 5 minutes, following which 
150pl of secondary antibody, biotinylated rabbit anti-rat immunoglobulin (diluted 
1:300 with TBS) (Dako Ltd, UK), was applied for a further 30 minutes.
Finally, after washing with TBS, the tumour sections were incubated with a 
horseradish peroxidase-labelled Avidin-Biotin complex (Dako Ltd, UK) for 30 
minutes, and then rinsed again in TBS for 5 minutes. The bound primary antibody 
was then visualised by incubating the tumour sections for 5 minutes with liquid 
Diaminobenzidine Plus (dilution 1:50) (Dako Ltd).
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After rinsing the slides in tap water, the tumour sections were counterstained with 
Mayer’s haemalaum for 5 minutes, rinsed again in normal water and ‘blued’ in 
Scott’s for 1 minute before mounting. To facilitate the latter process, the slides were 
immersed into 3 separate baths of IMS, for minute each, and then into 2 subsequent 
baths of xylene for a total of 10 minutes. The slides were then mounted in dibutyl 
phthalate in xylene, and the tumour sections were then ready for assessment using 
light microscopy.
The negative control tumour sections were incubated with TBS instead of the 
primary antibody, and the cell line SKBR3, known to over-express HER-2, was used 
as a positive control.
2.10.4 Scoring of HM64.13 Immunostaining
The tumour sections were assessed using light microscopy and a magnification of 
200. The IHC staining was then scored by 2 independent observers, according to a 
defined protocol, and without prior knowledge of the patients’ outcome. Two patterns 
of staining were looked at -  cytoplasmic and membrane staining. Immunostaining 
was considered positive if > 10% of the tumour cells were stained by the antibody. 
The intensity of the immunostaining was also categorised as negative (0), weak (1 +), 
and strong (2+). Any disparity in scoring was resolved by simultaneous evaluation of 
the tumour section by both observers.
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2.11 Immunostaining with Anti-CD31 Antibody
Microvessels within the tumour can be identified using specific antibodies against 
CD31 antigen. CD31 is a platelet/endothelial cell adhesion molecule, which can be 
targeted with anti-CD31 antibodies to label vascular endothelial cells [Horak ER et 
al., 1992].
Because Dukes’ B colorectal patients have a lower incidence of developing distant 
metastases, and therefore a better prognosis, only Dukes’ C colorectal cancers were 
assessed for MVD. Ninety-one Dukes’ C colorectal cancer sections were stained for 
CD31 antigen. The JC70 monoclonal antibody (DAKO, Copenhagen), which 
recognises the CD31 antigen, was used as it is known to stain positively for vascular 
endothelial cells in routinely fixed paraffin sections [Parums DV et al., 1990].
The tumour sections were again selected following review of the tumour blocks. The 
block with the greatest cross-section of tumour was selected. The tumour section 
from this block was initially stained with haematoxylin and eosin to ensure that a 
representative section of invasive carcinoma was being used for the purposes of the 
study.
The microvessel immunostaining was performed on 3-pm paraffin-embedded 
tumour sections using a standardised streptavidin-biotin process. The slides were 
de-waxed (as described in section 2.10.3), following which antigen retrieval was 
performed. For this, the slides were placed (in a rack) in a pressure-cooker, and 
immersed in antigen unmasking solution (Vector Lab., CA., USA) diluted 1:100 in 
distilled water, and then pressure-cooked for 2 minutes. The tumour sections were
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then washed in TBS for 5 minutes, and then transferred to distilled water. They were 
then immunostained, using the anti-CD31 antibody, at a concentration of 1:100, 
diluted in ChemMate™ Antibody Diluent (Dako). A negative control was also 
performed for each tumour section, using a non-immune reagent (ChemMate™ 
Negative control, Dako). The immunostaining was performed on a Dako TechMate™ 
500 Plus, strictly according to the manufacturer’s recommendations. The 
immunostaining was via an automated system, and the washing of slides during this 
process was in specific Washing Buffers 1, 2, 3 and Water Wash. Washing Buffer 1 
was used during the first part of the procedure, and the formulation of this buffer 
contributed to the blocking of non-specific binding of the immunological reagents to 
the tissue sections. Washing Buffers 2 and 3 were identical and were used for the 
remaining part of the procedure.
Briefly, after de-waxing and antigen retrieval, the sections were incubated with the 
primary antibody, JC70, for 25 minutes, following which they were washed in 
Washing Buffer 1 (ChemMate™ Buffer Kit, Dako), for about 5 minutes, and then 
incubated with the biotinylated goat anti-mouse and anti-rabbit secondary antibody 
for a further 25 minutes. After washing again in Washing Buffer 1 and then Buffer 2 
for approximately 5 minutes, the slides were incubated with Peroxidase Blocking 
solution for 5 minutes. The sections were again washed in Washing Buffer 2 for 3-5 
minutes, and then incubated in streptavidin peroxidase for 25 minutes. After washing 
the slides in Buffer 2 and then Buffer 3 for approximately 2 minutes, they were 
incubated in the chromogen, diaminobenzidine solution, diluted in HRP Substrate 
Buffer, for 10 minutes. After a washing period of about 5 minutes in Buffer 3, the 
sections were then counterstained with ChemMate™ Haematoxylin, and then 
washed in Water Wash at the end prior mounting as described previously.
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2.12 Microvessel Density Determination
The CD31 -stained tumour sections were assessed using light microscopy. Each 
section was initially scanned at low power (X40) to identify areas within the cancer 
with the highest areas of microvessel density (‘hot spot’). The MVD was then 
determined by counting all vessels seen at a magnification of 200, in a set area of 
0.2 mm2. Five ‘hot spot’ areas within each tumour section were assessed for MVD, 
and the mean MVD calculated for each tumour.
To facilitate the counting of the microvessels, a digital camera (JVC TK-C1380) was 
used with Leica Qwin computer software, to capture the image of each ‘hot spot’ 
assessed. The area of assessment could then be accurately defined, and it was also 
possible to mark the counted vessel. This allowed more accurate counting as it 
eliminated the possibility of missing a vessel, and also prevented duplicate counting 
of a vessel (which could be clearly highlighted).
Initial attempts to use a computerised image analysis system to count the number of 
microvessels in 10 tumour sections, proved to be significantly less accurate than the 
method described above. The reason for this was the extremely low level of 
interference by non-microvessel structures allowed by the automated system.
Counting the intratumoral microvessels was carried out as previously described by 
Weidner et al [Weidner N et al., 1991]. A microvessel was defined as any brown 
staining endothelial cell, or clusters of cells, that were distinct from others, and 
present in the invasive component of the tumour. A visible lumen was not necessary 
for the vessel to be included in the count. The assessment of the MVD was
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performed without any knowledge of the patients’ survival or the presence of distant 
metastases, or any other clinico-pathological variables.
2.13 Statistical Analysis
Statistical analyses were performed using the SPSS package (version 11.0). 
Correlation between clinico-pathological characteristics and the IHC scores was 
tested using x2 tests, at a significance level of p<0.05.
Non-parametric analysis, using the kappa test, was used to determine the level of 
agreement of the IHC scores between observers.
The association between the IHC scores and survival was estimated using Cox 
proportional hazards regression analyses. The end-point for the survival analyses 
was overall survival. Other covariates considered for inclusion in the model were site 
and size of tumour, depth of tumour invasion (i.e. T stage), grade, lymphovascular 
invasion, and node stage (N1 or N2) and presence of apical node metastases (the 
latter two for Dukes’ C cancers only). A Cox proportional hazards model was also 
used to assess the association of tumour variables, local relapse, site of relapse, 
distant metastases, and treatment with survival. Analyses were performed in which 
the survival analyses were stratified by Dukes staging, as this is currently the most 
important independent prognostic factor. Kaplan-Meier survival curves were 
computed, and the log rank test was used to test differences between the survival 
curves for the patient sub-groups. A p-value of less than 0.05 was considered 
significant.
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Chapter Three 
in vitro Studies with Anti-HER-2 Antibodies in Human 
Colorectal Tumour Cell Lines
Overexpression of HER-2 has been demonstrated in a panel of human tumor cell 
lines of different origins including breast, ovarian and gastric cancer cell lines [Lewis 
GD et al., 1993]. In this chapter, following the characterisation of anti-HER-2 mAb 
HM64.13, the expression of HER-2 in a panel of human tumour cell lines was 
determined, and then the effect of HER-2 or EGFR blockade, by antibodies, on the 
growth of such cell lines in vitro was investigated.
3.1 Specificity of mAb HM64.13
Monoclonal antibody HM64.13 was raised against the external domain of HER-2 on 
the breast carcinoma cell line SKBR3. This antibody was developed by Dr Helmout 
Modjtahedi while working at The Institute of Cancer Research, Sutton and further 
characterisation of this antibody was conducted at The University of Surrey. The 
specificity of mAb HM64.13 (lgG2b) for HER-2 was determined by differential binding 
assay, immunoprecipitation studies, and FACS analysis. This antibody was 
subsequently used in the examination of human colorectal tumour specimens, to 
investigate HER-2 expression.
The binding of mAb HM64.13 to a panel of human tumour cell lines that express a 
high or low level of HER-2 was determined by in-direct radioimmunoassay. Human 
tumor cell lines were incubated in the presence of 150nM of each mAb or control
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medium for 1 hour, on ice. The bound antibodies were then detected using 125l-Star 
71, as described in section 2.6 [Styles JM et al., 1990]. The differential binding of 
HM64.13 to human tumour cell lines that express a high (SKBR3, SKOV3), or low 
(HN5, MCF-7) level of HER-2 are shown in Figure 1. Indeed, the binding pattern of 
mAb HM64.13 to these cell lines was similar to that of the positive control anti-HER-2 
mAb ICR12 [Dean CJ et al., 1993; Styles JM et al., 1990]. This is in agreement with 
previous studies which have shown high levels of HER2 overexpression in SKBR3 
breast cancer cell line and SKOV3 an ovarian cancer cell line [Boente MP et al., 
1998; Lewis GD et al., 1993]. In addition the binding of mAb ICR62, which is directed 
against the EGFR, was highest in HN5 cells which express the highest level of the 
EGFR [Modjtahedi H and Dean C, 1996].
The specificity of mAb HM64.13 for the product of the c-erbB-2 proto-oncogene was 
investigated further by immunoprecipitation studies, using the [35S]-methionine- 
labelled proteins from SKBR3 cells. The immunoprecipitate was then analysed by 
SDS polyacrylamide gel electrophoresis, as described in section 2.5.
Fig. 2 shows the autoradiographs of the gel obtained following SDS-PAGE of 
immunoprecipitates prepared with antibodies HM64.13 and ICR12 (positive control). 
The results show that like anti-HER-2 mAb ICR12, mAb HM64.13 
immunoprecipitated specifically the p185HER'2 protein from Triton X-100 extracts of 
[35S]-methionine labelled SKBR3 cells. The control medium, as expected, shows no 
immunoprecipitation.
The known differential expression of HER-2 and EGFR by SKBR3 and HN5 cells 
respectively, was also used to confirm the specificity of mAb HM64.13, using FACS
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Chapter Three in vitro Studies with Anti-HER-2 mAbs
Figure 1. Differential binding of mAb HM64.13 to a panel of human 
tumour cell lines which express high (SKBR3 and SKOV3) or low (HN5, 
MCF-7) levels of HER-2. Confluent cultures of human tumour cell lines 
were incubated with 150nM of anti-HER-2 (HM64.13 or ICR12) or anti- 
EGFR (ICR62) mAb, or control medium, for 1 hour on ice. Then the 
bound antibody was detected by addition of 125l- goat anti-(rat IgG) 
polyclonal antibody (Star 71) (105cpm/well), as described previously 
[Styles JM et al., 1990; Modjtahedi H et al., 1997].
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Page 66
Chapter Three in vitro Studies with Anti-HER-2 mAbs
Figure 2. Specificity of mAb HM64.13 for HER-2. Like positive control 
mAb ICR12, HM64.13 conjugated to protein G sepharose 4B 
immunoprecipitated the p-185HER'2 from [35S]-methionine-labelled 
extract of SKBR3 cells [Styles JM et al., 1990; Modjtahedi H et al., 
1993b].
Chapter Three in vitro Studies with Anti-HER-2 mAbs
analysis. In this study, the human colorectal cell line DiFi, which is known to over­
express EGFR (4.8 x 106 receptors/cell) [Gross ME et al., 1991] was also used. After 
mixing 106 cells with 10 pig of each mAb, HM64.13 (anti-HER-2) or ICR62 (anti- 
EGFR), at 4°C for 1 hour, the cells were washed twice prior to incubation with FITC 
goat anti-rat IgG antibody, again at 4°C for 1 hour. After further washing and 
centrifugation of the cells, the cell pellet was re-suspended in FACSFlow, and 
analysed in a FACScan.
The results of the FACS analysis are presented in Figure 3. As the results with mAb 
HM64.13 show, HER-2 expression is significantly higher in SKBR3 in comparison to 
both HN5 and DiFi cells. The latter two cell lines are both EGFR overexpressing cells 
[Cowley G et al., 1984; Gross ME et al., 1991], as was demonstrated by the higher 
level of binding by the anti-EGFR mAb ICR62.
These data show a distinct profile for the anti-HER-2 and anti-EGFR mAbs, and 
support the findings above which suggest that HM64.13 specifically recognizes 
p185HER'2.
3.2 The Expression of HER-2 in other Human Colorectal Cell Lines
The level of expression of HER-2 in a panel of colorectal cell lines was investigated 
using mAb HM64.13 as the primary antibody, and the bound antibody was detected 
using an iodinated anti-rat polyclonal secondary antibody (STAR 71), as described in 
section 2.6. In this differential binding assay, the 4 additional human colorectal cell 
lines examined included CCL228, CCL244, CCL225, and CCL221, in addition to the
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Figure 3. Fluorescence-activated cell sorting histograms of * 
anti-HER-2 mAb HM64.13 and anti-EGFR mAb ICR62 binding 
to human tumour cell lines. The medium represents 
background fluorescence (binding of fluorescein- 
isothiocyanate-labelled goat anti-rat IgG in the absence of 
mAbs HM64.13 or ICR62). Cell lines analysed are: A) SKBR3 
human breast carcinoma; B) HN5 head and neck carcinoma; 
C) DiFi colorectal carcinoma
Page 69
Chapter Three in vitro Studies with Anti-HER-2 mAbs
control cell lines, SKBR3 and HN5, which over-express HER-2 and EGFR 
respectively.
As the results in Fig. 4 show, using the anti-HER-2 mAb HM64.13, the expression of 
HER-2 in a panel of human colorectal cell lines was much lower than that in the 
human breast tumour cell line SKBR3. This is in agreement with Lewis et al who 
showed low levels of HER-2 overexpression in colorectal cell lines compared with 
breast tumour cell lines such as SKBR3 [Lewis GD et al., 1993].
Interestingly, in contrast to DiFi cells (Fig. 3) and HN5 cells, these colorectal cell 
lines were also found to express low levels of EGFR (Fig. 4).
3.3 Growth Inhibition Studies
Having shown that the level of expression of HER-2 in the colorectal cell lines 
examined above was not as high as that seen in breast cancer cell line SKBR3, next 
the effect of antibody-blockade of HER-2, antibody blockade of EGFR, or EGFR 
blockade using a small molecule tyrosine kinase inhibitor, gefitinib, was investigated.
Three human colorectal cell lines were used in this study -  DiFi, CCL218, and 
CCL244. SKBR3 cells were also used. The cell lines were incubated with each of the 
anti-HER-2 antibodies, HM64.13 and ICR12, the anti-EGFR mAb ICR62, gefitinib, 
and EGF. After 4-7 days incubation, the proliferation of each cell line was compared 
with the untreated control.
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Figure 4. Level of expression of HER-2 and EGFR in a panel of human 
colorectal cancer cell lines, using anti-HER-2 mAb HM64.13 and anti- 
EGFR mAb ICR16, respectively. Confluent cultures of colorectal cancer 
cell lines were incubated with 150nM of mAb or control medium for 1 
hour on ice and then bound antibody was detected by the addition of 
125l-Star 71(105cpm/well), as previously described [Styles JM et al., 1990; 
Modjtahedi H etal., 1997].
7000 i
6000 -
a
o
■oc
3
5000 -
m 4000 - □  ICR16
□  HM64.13 
■  Medium< 3000 -
H
C0
8  2 0 0 0  -  Y”
1 0 0 0  H
Page 71
Chapter Three in vitro Studies with Anti-HER-2 mAbs
Figures 5A -  5D illustrate the results of the in vitro growth inhibition studies. At a 
concentration of 150nM, mAbs HM64.13 and ICR12 did not show any significant 
effect on the proliferation of the colorectal cell lines. However, in contrast to the cell 
lines CCL244 and CCL218, which showed no growth inhibition with gefitinib or the 
anti-EGFR mAb, DiFi showed significant inhibition of cell proliferation with the 
tyrosine kinase inhibitor and also with ICR62. The growth of SKBR3, which is known 
to express substantial levels of HER-2, was not affected by HM64.13 or ICR12. At a 
concentration of 2 pM, gefitinib showed 22.3% growth inhibition of SkBR3 cells. 
Inhibition of HER-2- overexpressing breast tumour cell lines by gefitinib has also 
been reported previously [Moulder SL et al., 2001].
3.4 Summary
The anti-HER-2 mAb HM64.13 was raised against the external domain of HER-2 on 
the breast carcinoma cell line SKBR3. Specific differential binding was shown by 
HM64.13 to cell lines known to express high (SKBR3 and SKOV3) and low (HN5 and 
MCF-7) levels of HER-2 (Figure 1). Like the positive control antibody ICR12, mAb 
HM64.13 immunoprecipitated the 185 kDa protein from the 35S-extract of the HER-2- 
overexpressing cell line SKBR3 (Figure 2). A panel of colorectal cell lines was 
shown to express low levels of HER-2, and antibody blockade of HER-2 did not 
affect their growth in vitro (Figures 4, 5). This may suggest that the HER-2 epitope 
being blocked by HM64.13 does not play a significant role in the growth signal 
transduction pathway in these colon cancer cells. Alternatively, the low level of 
expression of HER-2 in these cells might indicate that growth receptors, other than 
HER-2, play a more important role in their proliferation (please see discussion 
chapters).
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Chapter Four Prognostic Significance of HER-2
Chapter Four 
Expression Patterns and Prognostic Significance of HER-2 in 
Colorectal Cancer
Although the clinical significance of HER-2 overexpression is uncertain in many 
human tumours, HER-2 has been shown to be of prognostic value in breast cancer 
[Slamon DJ et al., 1987], and furthermore may predict for response to treatments 
[Newby JC et al., 1997]. A number of studies have examined the prognostic utility of 
HER-2 overexpression in colorectal cancer, and reached conflicting conclusions. The 
aim of this study was to examine the overexpression of HER-2 in colorectal cancer 
sections, using a standard avidin-biotin immunohistochemical technique and 
HM64.13 anti-HER-2 mAb. The localisation of this mAb is described and its 
prognostic significance discussed.
4.1 Patient Details
One hundred and seventy patients with Dukes’ B and C colorectal cancers were 
included in this study, and Table 4.1 shows the clinicopathological features of the 
study group. Eighty-one patients were male, and 89 were female. Their age ranged 
from 40 to 92 years (median 70 years; mean 70 years), and the median follow up 
time was 5.0 years. There were 65 Dukes’ B and 105 Dukes’ C cancers in this study 
cohort. Five Duke’s B patients and 63 Dukes’ C patients had received adjuvant 
chemotherapy (mainly 5-fluorouracil-based), whilst 5 and 32 patients respectively
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Table 4.1 Clinico-pathological characteristics of 170 colorectal cancer 
patients by Dukes’ staging
NUMBER OF PATIENTS 
DUKES’ B DUKES’ C 
N=65 N=105
Sex
Male 26 55
Female 39 50
Tumour site
Right colon 28 29
Left colon 18 30
Rectum 19 46
Size
<5cm 40 72
>5cm 25 33
Differentiation
Well 14 3
Moderate 36 56
Poor 14 40
Mucinous 1 6
Lymphovascular invasion
Absent 59 79
Present 6 26
T stage
T2 - 15
T3 55 64
T4 10 26
Apical node (Dukes’ C)
Negative - 56
Positive - 12
Unknown - 37
Positive Nodes (Dukes’C)
1 -3 nodes - 68
4+ nodes - 37
Adjuvant chemotherapy
Yes 5 63
No 60 42
Radiotherapy
Yes 5 32
No 60 73
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had received standard pelvic radiotherapy, as part of their post-operative 
management.
The mean (±SD) survival of the Dukes’ B patients was 7.1 (± 3.7) years, whilst for 
the Dukes’ C patients, it was only 4.6 (± 2.7) years. The Kaplan-Meier plots stratified 
for Dukes’ staging (Fig. 6) show that there was a significant difference in the survival 
of the Dukes’ B and C patients (p=0.00). Whereas the median survival of the Dukes’ 
C patients was 6.9 years, the median follow-up of the Dukes’ B patients had not yet 
been reached, at a maximum follow-up time of 11.9 years.
The significantly better survival seen in the Dukes’ B patients, compared to the 
Dukes’ C patients in this study, is consistent with the fact that Duke’s stage is one of 
the most important prognostic factors in colorectal cancer currently.
4.2 Immunostaining of Colorectal Cancer Sections with HM64.13
The overexpression of HER-2 was examined immunohistochemically in 170 
colorectal cancer sections, using the mAb HM64.13. There was heterogenous HER- 
2 immunostaining within the same tumour section. The predominant localisation of 
HER-2 immunostaining was cytoplasmic. Membrane HER-2 was seen with less 
frequency than cytoplasmic HER-2, and always in combination with cytoplasmic 
HER-2 on the tumour section.
Figure 7A illustrates a case of colorectal cancer showing strong cytoplasmic HER-2 
immunostaining. Figure 7B shows the typical immunostaining seen in the majority of 
the tumour sections, with predominant cytoplasmic immunostaining and some
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Figure 6. Kaplan-Meier curves for overall survival in 170 patients with 
colorectal cancer, stratified for stage Dukes’ B or Dukes’ C. There 
was a significant difference in the survival of these two groups of 
patients (p=0.000) (log rank test).
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Figure 7. Colorectal cancer section showing HER-2 
immunostaining using mAb HM64.13. (A) Shows a case of 
colorectal cancer showing strong cytoplasmic HER-2 
immunostaining. (B) Illustrates a case of predominant cytoplasmic 
HER-2, and some membrane HER-2 immunostaining. (C) Shows 
the corresponding negative control, where the primary antibody has 
been omitted (magnifications: A-C, 200X)
Figure 7 (continued). Colorectal cancer section showing HER-2 
immunostaining using mAb HM64.13 (A) Shows a case of 
colorectal cancer showing strong cytoplasmic HER-2 
immunostaining. (B) Illustrates a case of predominant cytoplasmic 
HER-2, and some membrane HER-2 immunostaining. (C) Shows 
the corresponding negative control, where the primary antibody 
has been omitted (magnifications: A-C, 200X)
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membranous HER-2 immunostaining, whilst Figure 7C shows the corresponding 
negative control where the primary antibody has been omitted.
There was very good agreement of the IHC scores between the 2 observers (kappa 
0.88). The level of HER-2 overexpression in this cohort of Dukes' B and C cancer 
patients was quantified (Table 4.2). Eighty-seven percent of cases showed positive 
cytoplasmic HER-2, and over half of these exhibited strong intensity (2+) 
immunostaining. 41% of cases showed positive membrane HER-2, with 91% of 
positive cases exhibiting strong immunostaining.
Figure 8 shows the human breast tumour cell line, SKBR3, immunostained with anti- 
HER-2 mAb, HM64.13. This illustrates that the pattern of staining in this cell line 
includes strong membranous staining. This is similar to that seen in human breast 
tumour sections, immunostained for HER-2. As SKBR3 is known to over-express 
high levels of HER-2, SKBR3 pellet sections were used as a positive control for 
HER-2 immunostaining of the colorectal cancers.
4.3 Prognostic Significance of HER-2 Immunostaining
The data was stratified for Dukes’ staging, as this is known to be the most significant 
prognostic factor in colorectal cancer currently. In the Dukes’ C group, multivariate 
analyses showed tumour grade, depth of tumour invasion, positive apical node, and 
positive cytoplasmic HER-2 to be independent prognostic factors (Table 4.3). A 
significantly better overall survival was seen in those patients exhibiting positive 
cytoplasmic HER-2, with a Hazard Ratio (HR) of 0.46 (Cl95 0.24-0.87, p=0.018) (Fig. 
9).
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Table 4.2. One hundred and seventy colorectal tumour sections were 
immunohistochemically stained, using anti-HER-2 mAb HM64.13 and a 
standard avidin-biotin horseradish peroxidase system. Using light 
microscopy, at 200X magnification, two patterns of immunostaining 
were assessed - membrane and cytoplasmic. The immunostaining was 
considered positive if > 10% of the tumour cells were stained by the 
antibody. The intensity of the immunostaining was also categorised as 
negative (0), weak (1+), and strong (2+). The scoring was performed by 2 
independent observers.
Membrane
HER-2
n (%)
Cytoplasmic
HER-2
n (%)
HER-2:
Positive 71 (41.2) 147 (86.5)
Negative 99 (58.8) 23(13.5)
Intensity of HER-2
Immunostaining:
Negative 99 (58.2) 23 (13.5)
Weak (1+) 3(1.8) 55 (32.4)
Strong (2+) 68 (40) 92 (54.1)
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Figure 8. Immunostaining of the HER-2-overexpressing SKBR3 cell line 
pellet with anti-HER-2 mAb HM64.13 (A) or with no primary antibody (B) 
(Magnification 200X). SKBR3 cell line was grown to confluence and then 
fixed with formalin, following pellet formation, by centrifugation at 1600 
rpm for 5 minutes. After two washes in formaldehyde, the pellet was re­
formed and then embedded in paraffin wax. Cell line sections were 
immunostained using a standard avidin-biotin immunocytochemistry 
technique.
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Table 4.3 Multivariate analyses of 105 Dukes’ C colorectal cancer 
patients showed tumour grade, depth of tumour invasion, positive apical 
node, and positive cytoplasmic HER-2 to be independent prognostic 
factors. The end-point of the analyses was overall survival.
Factor Number
(n=105)
Hazard Ratio 95%
Confidence
Interval
P value
Cytoplasmic
HER-2
Negative 17 Reference
Positive 88 0.46 0 .2 4 -0 .8 7 0.018
Differentiation
Mucinous 6 0.43 0 .1 2 -1 .5 4 0.196
Well 3 3.31 0 .8 7 -1 2 .6 0 0.080
Moderate 56 Reference - -
Poor 40 1.80 1 .0 6 -3 .0 8 0.031
T stage
T2 15 0.83 0.36 -1 .9 3 0.668
T3 64 Reference - -
T4 26 2.31 1.28-4.19 0.006
Apical node
Negative 56 Reference - -
Positive 12 3.15 1.53 - 6.48 0.002
Unknown 37 1.33 0 .7 2 -2 .4 4 0.359
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Figure 9. Kaplan-Meier plots of overall survival of 105 Dukes’ C 
colorectal cancer patients. Positive cytoplasmic HER-2 immunostaining 
was associated with a significantly better survival (p=0.018).
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This improved survival was not significantly different between those patients who 
received and those who did not receive chemotherapy (p=0.25). On univariate 
analyses, strong intensity cytoplasmic immunostaining was associated with depth of 
tumour invasion, with T3 tumours showing a higher proportion of strong cytoplasmic 
immunostaining than the T4 tumours (p=0.013) (data not shown).
No significant association was seen between cytoplasmic HER-2 overexpression 
and clinical outcome in the Dukes’ B cancers (Fig 10), but this may be due to the 
small number of deaths in this sub-group. In addition, no significant association was 
seen between membrane HER-2 and clinical outcome in either the Dukes’ B or C 
cases.
4.4 Summary
Colorectal cancer expresses high levels of HER-2. In this study, it was found that 
the predominant pattern of HER-2 immunostaining seen in colorectal cancer is 
cytoplasmic, and that cytoplasmic HER-2 overexpression was associated with a 
significantly better prognosis in Dukes’ C cancers. No such association was seen in 
Dukes’ B cancers, but this may be as a result of the small number of events in this 
sub-group.
Membranous HER-2 overexpression was found in 41.2% of tumours. While there 
was no association between this factor and clinical outcome in ether the Dukes’ B or 
C colorectal cancers, the high level of membranous HER-2 in colorectal cancer could 
make it an ideal target for monoclonal antibody-based immunotherapy (please see 
discussion chapter).
Page 86
Chapter Four Prognostic Significance of HER-2
Figure 10 Kaplan-Meier plots of overall survival of 65 Dukes’ B 
colorectal cancer patients. There was no significant association 
between positive cytoplasmic HER-2 immunostaining and 
outcome.
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Chapter Five 
Expression and Prognostic Significance of CD31 in 
Colorectal Cancer
Tumour angiogenesis has been shown to have a significant association with 
prognostic outcome in a number of solid tumours, including breast, prostate, and 
lung [Macchiarini P et al., 1992;Weidner N et al., 1992;Weidner N et al., 1993]. In 
this study, the quantitative expression of angiogenesis in colorectal cancer was 
determined, and its association with clinico-pathological factors and survival is 
reported.
5.1 Patient Details
There were 91 patients in this study, and they were a sub-group of the HER-2 study 
population as described in section 2.9. The median age at diagnosis was 70, with a 
range from 40 to 86 years, and the median follow-up time was 4.2 years (range 0.32- 
10.86 years). There were 49 male and 42 female patients. Sixty-two patients had a 
tumour ^5 cm in maximum dimension and 29 patients had a tumour of >5 cm.
Table 5.1 shows some of the important clinicopathological features of the 91 
patients in this study, all of whom had a Dukes’ C colorectal cancer. Twenty-five 
patients had evidence of lymphovascular invasion in their tumour, and overall, 39 
patients developed distant metastases, whilst 5 had local (either anastamotic or 
nodal) recurrences. Fifty-three and 28 patients received adjuvant chemotherapy and 
pelvic radiotherapy, respectively.
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Table 5.1 Median Microvessel Count in 91 patients with colorectal 
cancer (non-parametric test Pearson x2test)
Number of 
cases
Median 
microvessel 
count (25-75% 
quartiles)
P value
Size of tumour
< 5 cm 62 26 (13-37)
> 5 cm 29 27 (14-44) 0.63
Depth of invasion
T2 11 33 (13-39)
T3 57 26 (13-30)
T4 23 27 (11-44) 0.81
Positive nodes
1 -3 nodes 60 26 (13-42)
4+ nodes 31 27 (13-32) 0.38
Apical node involvement
Negative 45 28 (18-46)
Positive 11 27 (13-32)
unknown 35 18(10-30) 0.60
Lymphovascular invasion
Negative 66 26 (13-42)
Positive 25 27 (7-32) 0.73
Grade
Mucinous 6 12 (4-20)
G1 2 36 (14-57)
G2 48 26 (13-35)
G3 35 28 (13-42) 0.22
Site of recurrence
None 47 26 (13-38)
Local 5 17(13-36)
Distant 39 28(11-42) 0.92
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5.2 Immunostaining of CD31
CD31 immunostaining revealed heterogeneity of MVD in the colorectal cancer 
specimens. There were clear ‘hot spots’ of high intratumoral neoangiogenesis, and 
these areas were localised at low power (X40), using light microscopy. Five ‘hot spot’ 
areas were then assessed, at 200X magnifications, and for each ‘hot spot’ the 
number of microvessels in a set area of 0.2 mm2 was counted, and the mean MVD 
(per 0.2 mm2) was calculated for each tumour.
Figure 11A shows a colorectal tumour stained immunohistochemically with anti- 
CD31 mAb, JC70. It illustrates the brown staining seen with this mAb highlighting the 
endothelial cells of the microvessels. Figure 11B shows the corresponding negative 
control slide, using non-immune anti-sera.
5.3 Prognostic Significance of CD31 Immunostaining
The median MVD for the 91 patients was 26 (range 0-100). As described previously 
by Vermeulen et al., [Vermeulen PB et al., 1999], and others JTakebayashi Y et al., 
1996; Tanigawa N et al., 1997], 2 sub-groups were defined using the median MVD 
as the cut-off for the groups. The patients were therefore divided into those with low 
(< 25) and those with high (>25) MVD tumours.
In this study, MVD of colorectal carcinomas showed no association with the patients’ 
age (p=0.53) or size of tumour (Table 5.1). No significant difference in tumour MVD 
was seen between patients with or without haematogenous spread of their disease. 
The median tumour microvessel count in those 39 patients who developed distant 
metastases was 28, in the areas of highest neovascularisation. In
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those 47 patients who remained disease-free, the corresponding value was 26. 
Therefore, no difference in the degree of tumour neovascularisation was seen in 
these two groups (p=0.41). Furthermore, MVD did not predict for the type of 
recurrent disease (e.g. distant versus local) nor for the site of distant metastases 
(e.g. liver or lung).
The evaluation of MVD in relation to other clinico-pathological variables is shown in 
Table 5.1. No difference in the MVD was demonstrated in tumours of different nodal 
stage (p=0.38), or those with or without apical node metastases (p=0.60). 
Furthermore, those tumours which demonstrated vascular invasion histologically, 
showed no significant difference in their MVD compared to tumours with no vascular 
invasion (p=0.73). There was no association between depth of tumour invasion 
through the bowel wall and MVD (p=0.81). In addition, no association was found 
between tumour MVD and expression of membranous or cytoplasmic HER-2 (using 
mAb HM64.13) (data not shown).
On multivariate analysis (91 patients), the presence of apical node metastases was 
the only significant independent prognostic indicator (HR 5.1, 95CI 2.2-11.8, 
p=0.000). The presence of a T4 tumour almost reached statistical significance (HR 
3.3,95CI 0.9-12), p=0.07).
The survival rates for the 91 patients according to their MVD sub-group was 
calculated using the Kaplan-Meier method (Figure 12). There was no significant 
difference in survival between those patients with tumours with high MVD and those 
with low MVD tumours (p=0.349).
Page 92
Chapter Five Prognostic Significance of CD31
Figure 12. Overall survival curves for 91 patients with colorectal 
cancer. Survival of patients with low and high MVD tumours. There 
was no significance difference in the survival of the patients in 
these 2 groups using the log rank test (p=0.349).
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5.4 Summary
Using mAb CD31, the microvessel density of ninety-one Dukes’ C colorectal 
cancers were assessed. There was no association seen between MVD and 
recurrence, and survival in this group of patients. There was also no association 
between MVD and HER-2 overexpression. In this study, MVD did not seem to act as 
a predictor for poor outcome.
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Chapter Six 
Discussion and Conclusion
Despite advances in new chemotherapies (e.g. oxaliplatin and irinotecan) used 
following surgery for colorectal cancer, the overall prognosis remains relatively poor, 
with a mean 5-year survival rate of approximately 50%. Currently, lymph node 
involvement and the number of positive nodes are considered amongst the most 
important prognostic indicators in colorectal cancer [Gastrointestinal Tumor Study 
Group, 1985; Wolmark N et al., 1986]. However, the lymph node status alone does 
not always predict the accurate outcome of the patient. A significant number (about 
30%) of Dukes’ B colorectal cancer patients will develop progressive disease, and for 
this group, the decision regarding adjuvant chemotherapy remains difficult, using the 
prognostic indicators available to us at present. Large randomised studies have failed 
to show a definite survival advantage from adjuvant chemotherapy in Dukes’ B 
colorectal cancers [International Multicentre Pooled Analysis of Colon Cancer Trials 
(IMPACT) investigators, 1995; Mamounas E et al., 1999]. The recent report from the 
large randomized Quasar 1 study investigating the role of adjuvant chemotherapy in 
Dukes’ B cancers has disappointingly also failed to show a significant benefit 
(unpublished data). Furthermore, a subgroup of tumours from 647 Dukes’ B patients 
has been assessed with regard to pathological and histochemical variables. On 
multivariate analysis, vascular invasion (p=0.022) and serosal involvement (p=0.024) 
were the only significant prognostic variables.
However, there are an increasing number of studies in solid tumours indicating that 
protein markers may play a significant role in predicting recurrence and survival.
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Consequently, there has been a shift towards looking at the molecular phenotype of 
cancer cells to see if this can help us to define molecular markers which may help 
predict prognosis more accurately so that we can better select those patients in a 
poorer prognostic group who should be offered adjuvant therapies. Furthermore, 
identification of these proteins may facilitate newer treatments. This strategy has 
been particularly successful in breast cancer patients where the role of HER-2 has 
been established in predicting not only outcome but response to treatments. 
Furthermore, in breast cancer, a specific monoclonal antibody directed against HER- 
2 (Trastuzumab™) has been developed and approved for clinical use in patients 
whose tumours over-express HER-2 [Slamon DJ et al., 2001].
The role of HER-2 has also been investigated in colorectal cancer, but the results 
have been inconsistent. The aim of the present study was to investigate the 
prognostic value of Human Epidermal Growth Factor Receptor-2 (HER-2) and 
microvessel density in colorectal cancer. Furthermore in vitro studies were also 
performed to investigate the expression pattern of HER-2 in a panel of human colon 
tumour cell lines and the effect of antibody blockade of HER-2 on the growth of these 
cell lines.
6.1 The Expression of HER-2 in Human Tumour Cell Lines
The anti-HER-2 mAb HM64.13, used in this study, was raised against the external 
domain of HER-2 on the human breast carcinoma cell line SKBR3 [Lewis GD et al.,
1993]. The specificity of this mAb for HER-2 was then demonstrated by differential 
binding assay, immunoprecipitation studies, and FACS analysis, as shown in Figures
1-3.
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Next, using anti-HER-2 mAbs HM64.13 and ICR12, the expression of HER-2 was 
examined in a panel of human colorectal cell lines. As the results presented in Figure 
4 show, the level of expression of HER-2 on colorectal cell lines was much lower 
than on human breast carcinoma cell lines. This is in agreement with the findings of 
Lewis et al who also found lower levels of p185HER'2 in most of the colorectal cell 
lines used [Lewis GD et al., 1993].
The effect of HER-2 blockade on the proliferation of human colorectal cell lines was 
then examined using HM64.13 and the control mAb ICR12. Figures 5A-5C show that 
anti-HER-2 mAbs HM64.13 and ICR12 did not have any significant inhibitory effect 
on the proliferation of the colorectal cell lines, at a concentration of 200 nM.
The low level of expression of HER-2 in colorectal cell lines may help to explain the 
lack of inhibition of cell growth seen with HM64.13 and the control mAb ICR12. With 
a lower number of receptors available for antibody-mediated blockade, any potential 
inhibitory effect may be of a smaller magnitude. However, interestingly, the breast 
cancer cell line SKBR3, which is known to over-express a high level of HER-2, also 
showed no significant growth inhibitory effect with HM64.13 and ICR12 (Figure 5D). 
Thus, in the current study, there was no relationship between p185HER‘2 
overexpression and antibody-mediated anti-proliferative effect. This phenomenon 
has previously been described for other tumour cell lines (e.g. gastric and colon cell 
lines) [Lewis GD et al., 1993], and it is unclear why some p185HER'2-overexpressing 
tumour cells show insignificant growth inhibition with anti-HER-2 monoclonal 
antibodies.
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One hypothesis is that the functional activity of an anti-HER-2 antibody is more 
related to the epitope that it recognizes than to its antigen binding affinity. It has 
previously been shown that various anti-HER-2 mAbs inhibit cell growth in vitro with 
varying efficiency [Hudziak RM et al., 1989; Tagliabue E et al., 2004]. Furthermore, 
Xu et al. reported that anti-HER-2-mediated growth inhibition was via 
immunochemically and functionally distinct epitopes on the extracellular domain of 
the c-erbB-2 receptor [Xu F et al., 1993]. Thus, the particular HER-2 epitope being 
blocked by mAb HM64.13 may not necessarily play an instrumental part in the 
growth signaling pathway, in that particular tumour cell line. This may explain why no 
significant anti-proliferative effect was seen with HM64.13 in the colorectal cell lines 
used in this study. Furthermore, in contrast to the anti-HER-2 mAbs used by Lewis et 
al (1993), it may explain why no growth inhibition of SKBR3 was seen with HM64.13 
or ICR12. It would suggest that distinct epitopes of HER-2 facilitate different aspects 
of its function. For example, it has also been demonstrated that different anti-HER-2 
immunotoxins targeted against different epitopes of the p185HER‘2 protein exert 
different cytotoxic activity [Boyer CM et al., 1999].
Interestingly, when the part of the signaling pathway downstream to the extracellular 
domain, was blocked, using the tyrosine kinase inhibitor, gefitinib, some growth 
inhibition (22%) was seen in SKBR3 cells (Fig. 5D).
With the exception of the DiFi cell line, treatment of the other human colorectal cell 
lines with anti-EGFR mAb ICR62 or gefitinib showed no significant effect on their 
proliferation. DiFi is known to over-express EGFR (4.8 x 106/cell) [Gross ME et al.,
1991], and showed significant anti-proliferative effect with both ICR62 and gefitinib.
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6.2 The Prognostic Role of HER-2 in Colorectal Cancer
In this study, the expression and prognostic significance of HER-2 was investigated 
in 170 colorectal cancer patients. Previous studies have revealed conflicting results 
in terms of the frequency and prognostic significance of HER-2 [McKay JA et al., 
2002; Osaka T et al., 1998; Sun X-F et al., 1995]. Here, cytoplasmic HER-2 was 
found to be an independent prognostic marker in Dukes’ C cancers, where positive 
cytoplasmic HER-2 was associated with a significantly better survival. However, this 
survival advantage was not seen in the Dukes’ B cancers, but this might be 
explained by the small number of events in this sub-group. No significant association 
was seen between membrane HER-2 and clinical outcome in either Duke’s B or C 
cases.
Previous studies investigating the prognostic role of HER-2 in colorectal cancer 
have given conflicting results, as illustrated in Table 6.1. However, the wide 
variability in the overexpression of HER-2 seen in these studies is not peculiar to 
colorectal cancer, and is well documented for other tumours including breast, ovary 
and bladder [Menard S et al., 2001]. From Table 6.1, one can see that moderate to 
strong membrane HER-2 expression in these colorectal cancers ranged from 1.4% 
to 81.9%. In addition, while membrane HER-2 was associated with a poor prognosis 
in one study [Knosel T et al., 2002], others showed no such association [Benecke M 
et al., 2002; Chamberlain NL et al., 1999; McKay JA et al., 2002]. Also of note is that 
even when the same anti-HER-2 antibody is used, marked differences in the levels 
of HER-2 overexpression are reported. For example, the range of HER-2 
overexpression seen in the three studies using anti-HER-2 antibody, NCL-CB11, 
was 33.5%-81.9% [Kay EW et al., 1994b; McKay JA et al., 2002; Sun X, 2001].
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Table 6.1. Summary of studies looking at the overexpression of 
cytoplasmic HER-2 and membranous HER-2 in colorectal cancer, 
and their prognostic role.
Investigator Number
of
patients
mAb Dukes’
staging
Reported 
Positive aCI 
and/or bMI
Hazard
Ratio
p VALUE
McKay JA et 
al., 2002
249 NCL-
CB11
A-D Ml 81.9% 
(Cl cnfa)
aNS
Sun X-F et al., 
1995
293 NCL-
CB11
A-C Ml 59% 
(Cl nfa)
e0.5 P=0.027
Kay EW et al., 
1994b
164 NCL-
CB11
B Cl 33.5% 
Ml 0%
2.51
(Positive
Cl)
P=0.0005
Benecke M et 
al., 2002
74 Hercep 
Test Kit
D Ml 9% 
(Cl nfa)
NS
Knosel T et al., 
2002
45 Hercep 
Test Kit
Not
specifie
d
Ml 49% 
(Cl nfa)
Ml
associated 
with poorer 
survival
‘significant’ 
but p value 
not stated
Kakani V et 
al., 2002
71 Hercep 
Test Kit
B Ml 1.4% 
(Cl nfa)
NS
Nathanson 
DR et al., 2003
139 Hercep 
Test Kit
A-D Ml 3.6% 
(Cl nfa)
NS
Osaka T et 
al., 1998
146 Nichirei A-D Ml 2.1% 
Cl 66%
1.82
(Positive
Cl)
P=0.008
Kapitanovic S 
et al., 1997
155 Ab-3 A-C Mixed Cl 
and Ml 
84%
1.84 
(Mixed Cl 
and Ml)
0.014
Chamberlain 
NL et al., 1999
96 Rabbit
anti-
HER2
A-D Ml 15.6% 
Cl 9.4%
NS
Lee JC et al., 
2002
125 Triton A-D Ml 4% “ NS
a Cl, cytoplasmic HER-2
b Ml, membrane HER-2 (2-3+ in all cases except in the case of Chamberlain et al where 
percentage indicates those cases with a score of 1 -3+) 
c nfa, not formerly assessed
d NS: not statistically significant at p<0.05; point estimates and exact p-values not given, 
e Only in aneuploid tumours with positive Ml
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Furthermore, there were also differences in the localization of the HER-2 
immunostaining (i.e. membranous or cytoplasmic), even when the same mAb was 
used. Using anti-HER-2 mAb NCL-CB11, Kay and colleagues investigated the 
expression of HER-2 in 164 patients with Dukes’ B cancers [Kay EW et al., 1994b]. 
Whilst they reported no evidence of membrane HER-2 in their group of tumours, all 
33.5% of the HER-2-positive cases showed cytoplasmic HER-2, and the latter was 
an indicator of poor clinical outcome in Dukes’ B cancers. In complete contrast to 
Kay’s study, Sun et al. reported a 59% incidence of membrane HER-2 
overexpression in 293 patients with locally advanced colorectal cancer, using the 
same mAb NCL-CB11 [Sun X-F et al., 1995]. Overall, there was no significant 
association found between membrane overexpression of HER-2 and survival, but 
surprisingly, a favourable survival was seen on subgroup analysis in DNA anueploid 
tumours. Cytoplasmic HER-2 was not quantified in this study. A third group, in 
Aberdeen, found no significant association between clinical outcome and positive 
membrane HER-2 in 249 colorectal tumours, again using NCL-CB11 [McKay JA et 
al., 2002]. They performed a semi-quantitative assessment of HER-2 
overexpression, according to the United States Food and Drug Administration (USA 
FDA)-approved scoring system [Jacobs TW et al., 1999]. However, this scoring 
system makes no provision for cytoplasmic HER-2 assessment, and so its incidence 
in this study is not reported.
Although membrane HER-2 alone has been shown to be of prognostic value in 
breast cancer, the intuitive assumption that this is the only important criterion for 
assessing HER-2 overexpression in other tumours, including colorectal cancer, may 
not necessarily be valid. There have been studies in breast [Zschiesche W et al.,
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1994] and thyroid [Sugg SL et al., 1998] cancer which have shown an association 
between good prognostic tumours and cytoplasmic HER-2. Cytoplasmic HER-2 has 
also been shown to be the predominant pattern of immunostaining in squamous cell 
carcinoma of the head and neck [Field JK et al., 1992].
6.3 Cytoplasmic HER-2 is Associated with a Better Survival
The current study, like others [Kay EW et al., 1994b; Osaka T et al., 1998], has 
found cytoplasmic HER-2 to be the predominant pattern of immunostaining in 
colorectal cancers (Table 4.2). However, to my knowledge, this is the first study in 
colorectal cancer to suggest a better survival associated with tumours showing 
positive cytoplasmic immunostaining (Figure 9). Furthermore, positive cytoplasmic 
HER-2 was found to be an independent prognostic marker (HR 0.46, p<0.02) in 
Dukes’ C colorectal cancer, together with grade and depth of invasion of tumour, and 
apical node metastases (Table 4.3).
Investigators from Croatia reported mixed cytoplasmic and membrane HER-2 
immunostaining in their cohort of colorectal cancer patients, and found that those 
cases with moderate or strongly positive tumours had a significantly poorer survival 
than those with weakly positive tumours [Kapitanovic S et al., 1997]. However, a 
median survival of only 2.3 or 0.5 years in patients whose tumours show moderate or 
strong HER-2 overexpression respectively is well below that expected in a cohort of 
patients with loco-regional disease. In another study, predominant cytoplasmic HER- 
2 immunostaining was described in the tumour specimens of 146 Japanese patients, 
and this was correlated with a poorer prognosis [Osaka T et al., 1998]. However, no 
prognostic significance was found for cytoplasmic or membrane HER-2 in 96
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tumours from an Australian cohort of patients [Chamberlain NL et al., 1999](see 
Table 6.1).
The varying IHC techniques and conditions, the different anti-HER-2 antibodies, 
which differ in their binding affinity and epitope specificity, along with differences in 
the interpretation of HER-2 overexpression (including not reporting cytoplasmic 
staining) are probably the main reasons for the controversies surrounding the 
prognostic significance of HER-2 in colorectal cancer [Kay EW et al., 1994a; Press 
MF et al., 1994], Any ethnic variability in the overexpression of HER-2 is unknown.
There is a definite need for a standardised system of reporting HER-2 
overexpression in colorectal cancer if there is to be any valid comparison of studies. 
Some investigators have attempted to use the USA FDA-approved scoring system in 
colorectal cancer [Jacobs TW et al., 1999]. However, although this scoring system 
allows standardisation of the assessment and scoring of membrane HER-2, it is not 
designed to score cytoplasmic HER-2 . The FDA-approved scoring system was 
developed to standardise the evaluation of HER-2/neu protein expression in breast 
cancers, using the HercepTest™ (DAKO, Glostrup, Denmark). In this context, where 
a decision regarding receptor-targeted antibody therapy (i.e.trastuzumab) is being 
considered, it is logical that the IHC scoring system assesses membrane 
immunostaining solely, as the antibody clearly has to bind the receptor to produce its 
effect. Any cytosolic form of HER-2, identified immunohistochemically, would be of 
no therapeutic value, in terms of antibody therapy, due to its reduced accessibility, 
and this would explain why scoring of the cytoplasmic HER-2 is not included in the 
therapy-focused FDA system. However, in attempting to identify a prognostic 
marker immunohistochemically, the criteria used to score the immunostaining need
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not be limited to a membrane-localised molecular marker. The predominant pattern 
of HER-2 immunostaining seen in colorectal cancer is cytoplasmic, with membrane 
immunostaining seen to a lesser extent. Whilst the precise significance of 
cytoplasmic HER-2 remains under investigation, any assessment of HER-2 
overexpression in colorectal cancer should ideally take into consideration 
cytoplasmic immunostaining of HER-2, as well as membrane HER-2.
In this study, it was found that the predominant pattern of HER-2 immunostaining 
seen in colorectal cancer is cytoplasmic. However, traditionally investigators have 
focused on the membranous overexpression of HER-2 {43}{45}. The suggestion that 
the transmembrane position of HER-2 argues against it being detected in the 
cytoplasm, and that cytoplasmic immunostaining is an artefact, has probably 
contributed to under-reporting of cytoplasmic HER-2, and any association with 
outcome. However, there is data to suggest that the precise significance of 
cytoplasmic HER-2 should be fully elucidated, and that it should not be ignored. 
Cytoplasmic HER-2 has been correlated with gene amplification in bladder [Coombs 
LM et al., 1991] and colorectal cancers [D'Emilia J et al., 1989; Kapitanovic S et al., 
1997]. The close correlation between cytoplasmic immunoreactivity and c-erbB-2 
amplification argues that the cytoplasmic product represents some form of the HER- 
2 protein product, possibly a splice variant of the whole receptor. In the colorectal 
cancer studies, Western blotting techniques were used to characterize the molecular 
weight of the cytosolic protein, which was found to be 155kDa or 185kDa 
[Kapitanovic S et al., 1997; Osaka T et al., 1998]. Using immunoprecipitation studies, 
a 160-kD protein was found in a human gastric cell line, which over-expressed HER- 
2 that was pre-treated with an N-linked glycosylation inhibitor [Akiyama T et al.,
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1986]. This protein was considered to be an incompletely glycosylated form of HER- 
2 .
There are studies to suggest that the truncated form of HER-2 may also be of 
prognostic value. The full-length receptor p185HER-2 undergoes a slow proteolytic 
shedding of its ECD from the surface of HER-2-overexpressing tumour cells in 
culture [Lin YL and Clinton GM, 1991; Pupa S et al., 1993]. The HER-2 ECD has 
been detected in the serum of patients with advanced breast cancer where it was 
shown to correlate with recurrence [Brandt-Rauf PW, 1995]. Furthermore, elevated 
levels of circulating HER-2 ECD have been shown to correlate with increased 
resistance to chemotherapy, in patients with metastatic breast cancer [Colomer R et 
al., 2000]. It has also been reported that, in contrast to the full-length HER-2, the 
membrane-associated p95HER-2 fragment, which is missing its ECD, is more 
frequently expressed in lymph node metastatic tissue than in primary breast cancer 
tissues [Molina MA et al., 2002]. This could have both therapeutic and prognostic 
implications if indeed the truncated kinase p95 is shown to have a role in the 
development of metastasis.
The association between membranous overexpression of HER-2 and a poorer 
prognosis, as seen in the breast studies, can be explained by our knowledge of 
HER-2 and its role in the signal transduction pathway. It is less clear from previous 
studies why cytoplasmic HER-2 overexpression should be associated with a poorer 
survival in colorectal cancer [Kay EW et al., 1994b; Osaka T et al., 1998] as the 
mitogenic growth signal is presumably down-regulated under these circumstances. 
The survival benefit seen with positive cytoplasmic immunostaining, as reported in 
the current study, may represent internalization and possible modification of HER-2.
Page 105
Chapter Six Discussion and Conclusion
With the receptor no longer on the cell surface, it is unable to form homodimers, or 
heterodimers with other receptors of the same EGFR family, leading to down- 
regulation of the mitogenic growth signals, not only mediated by HER-2 itself, but 
also by EGFR, HER-3 and HER-4 [Gullick WJ, 1990; Rubin I and Yarden Y, 2001]. 
In vitro studies, using cell lines overexpressing HER-2, have shown a shift from 
membranous to cytoplasmic immunostaining, apparently reflecting internalization of 
HER-2 , following activation of the receptor [Bacus SS et al., 1990;Bacus SS et al.,
1992]. This process is accompanied by decreased proliferative activity of the tumour 
cells. This would explain the reduced potential for tumour growth and progression, as 
reflected in the improved survival in those patients whose tumours show cytoplasmic 
HER-2.
Future large studies in colorectal cancer are required to both standardise the 
reporting of membrane and cytoplasmic HER-2 overexpression, and to confirm their 
prognostic role. Finally, the high level of membraneous HER-2 in this study (68 out of 
170 cases) could make HER-2 an ideal target for monoclonal antibody-based 
immunotherapy in such patients.
6.4 HER-2 Targeting
The transmembrane position of HER-2 lends itself to being an ideal target for 
antibody-mediated therapy. In breast cancer, HER-2 has been shown to be of 
significant prognostic value [Slamon DJ et al., 1987], and this has led to the 
development of the first anti-HER-2 monoclonal antibody, transtuzumab 
(Herceptin™), being used in the treatment of metastatic breast cancer. This 
therapeutic option has necessitated the determination of HER-2 status in those
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breast cancer patients in whom it is used, using their archival tumour specimens. 
The standardization of HER-2 immunostaining in breast tumour sections has been 
instrumental to identifying those patients for whom trastuzumab may be a 
therapeutic option.
There have been some reports suggesting that HER-2 may be of prognostic 
significance in other cancers, including those of the ovary, pancreas, stomach and 
colon. Most of these reports have looked at membranous HER-2 immunostaining, 
whilst others have acknowledged the presence of cytoplasmic HER-2, particularly in 
colorectal cancer, and its potential prognostic role in these tumours.
In the current study, there was no significant association between membrane HER-2 
and survival in Dukes’ B or C colorectal cancer patients. This was also true of the 
other large studies which assessed the prognostic role of membrane HER-2 in 
colorectal cancer [Benecke M et al., 2002; Chamberlain NL et al., 1999; McKay JA et 
al., 2002]. This does not necessarily suggest that anti-HER-2 antibody therapy would 
not have a significant role in the treatment of colorectal cancer. In addition, the 
interaction between HER-2 and other molecular proteins, via the signal transduction 
pathway, indicates that the association between HER-2 and clinical outcome may 
not be a linear one. Furthermore, since HER-2 does not have a known ligand of its 
own, it relies on heterodimerisation for its transactivation, and HER-2 is thought to be 
the preferred heterodimer partner in the HER signaling network [Klapper LN et al., 
2000]. Consequently, in colorectal cancer, it may be necessary to look at the 
overexpression of HER-2 not in isolation, but in relation to the co-expression of other 
cellular receptors or proteins, either from the same (e.g. EGFR) or different (e.g. 
insulin-like growth factor-1 [IGF-1] receptor) family. Furthermore, the strategy of
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specifically targeting HER-2 alone, with an anti-HER-2 mAb, may need to be 
reviewed in the context of the influence of other receptors known to play a significant 
role in the effectiveness of the mAb. Indeed, synergistic inhibition of growth in HER-
2-overexpressing breast cancer cells has been demonstrated by co-targeting HER-2 
and IGF-1 receptors [Camirand A et al., 2002]. Furthermore, recent experimental 
studies have indicated that the mechanism whereby tumour cells, previously 
sensitive to the anti-HER-2 mAb transtuzumab, subsequently develop a resistant 
phenotype is by up-regulation of other receptors such as IGF-1 R [Albanell J and 
Baselga J, 2001].
6.5 The Prognostic Role of CD31 Immunohistochemistry in Colorectal 
Cancer
New tumour growth, and subsequent progression to metastases, is dependent on 
the formation of new blood vessels to provide the essential requirements for this 
process (e.g. nutrition and oxygen) [Folkman J, 1990]. The first suggestion that the 
number of microvessels in a tumour could be related to metastases and survival was 
described in malignant melanoma [Srivastava A et al., 1988]. Since then, the 
prognostic information from tumour vascularity has been described for other tumour 
sites, including breast [Weidner N et al., 1992], lung [Macchiarini P et al., 1992], 
stomach JTanigawa N et al., 1996], and prostate [Weidner N et al., 1993].
In colorectal cancer, there is less known about the prognostic significance of tumour 
vascularity, and the studies to date reveal conflicting results, and are therefore by no 
means conclusive (Table 6.2).
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Table 6.2. Summary of studies looking at the prognostic 
significance of tumour vascularity in colorectal cancer
Investigator Number
of
patients
Dukes’
stage
Factor
assessed
Magnifi­
cation 
of field
Cut-off for 
MVD 
groups
Results of 
multivariate 
analysis
Saclarides TJ 
et al., 1994
48 A-D F8RA X100 39.5a 
(no cut­
off)
No multivariate 
analysis
Frank RE et al., 
1995
105 B F8RA X100
oCOCM No multivariate 
analysis
Bossi P et al., 
1995
178 A-D CD31 X200 115 a P=NS
Lindmark G et 
al., 1996
212 A-D F8RA X125 >10a/field longer survival 
on univariate 
analysis 
(P=0.007)
Takebayashi Y e 
al., 1996
166 A-C F8RA X400 65° P=0.007
Tomisaki S et 
al., 1996
175 A-D F8RA X200 32 a No multivariate 
analysis
Tanigawa N et 
al., 1997
133 A-D CD34 X200 105° P=0.0002
Takahashi Y  et 
al., 1997
27 B F8RA 200X 26 a High MVD 
correlated with 
time to 
recurrence
Choi HJ et al., 
1998
127 A-D F8RA X200 55a P=0.0004
Vermeulen PB., 
et al., 1999
116 A-C CD31 X 200 74° P=0.006
Sternfeld T  et 
al., 1999
146 A-C CD31 X200 75a P=NS
Pietra N et al., 
2000
119 B CD31 X1000 254a 
(no cut­
off)
P=NS
Cascinu S et 
al., 2000
121 B VEGF ‘High power’ >10%
positive
cells
Worse disease- 
free survival in 
VEGF positive 
cases (p=0.001)
Cianchi F et al., 
2002
84 A-B CD31 X250 45° P=NS
aMean MVD 
bMedian MVD
cmedian MVD at 66% percentile
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In the current study, the mean (±SEM) MVD for those patients who remained 
disease-free was 29 (± 3), whilst for those patients who developed a recurrence 
(local or distant), the mean MVD was 27 (± 3). There was thus no significant 
difference in the MVD seen in those tumours of patients with recurrence of their 
disease when compared with those from patients who remained disease-free. 
Furthermore, no association was found between MVD and other conventional 
prognostic factors such as the number of nodes involved with metastases, vascular 
invasion, depth of tumour invasion, and grade of tumour.
Two recent studies [Cianchi F et al., 2002; Pietra N et al., 2000] also found no 
significant correlation between MVD and recurrence rates or survival. However, both 
of these studies were in node negative colorectal cancers only, and therefore the 
results cannot be compared to the current study which included only Dukes’ C 
cancers. Node-negative colorectal cancer has a better prognosis than node positive 
disease since the incidence of subsequent distant metastases in the former group is 
significantly lower. Consequently, if angiogenesis does in fact have an independent 
prognostic role, in predicting those patients who will relapse with distant metastases, 
its may be more difficult to show in a multivariate analysis, particularly if the number 
of events in the study population is low. This is reflected in the fact that two further 
studies investigating the prognostic role of MVD in node-negative colorectal cancers 
[Frank R et al., 1995; Takahashi Y et al., 1997] both failed to show MVD as an 
independent prognostic marker for survival, and one of the studies [Frank R et al.,
1995] did not quote any multivariate analyses.
However, the current study which investigated Dukes’ C colorectal cancers failed to 
show any association between recurrence of disease or survival and MVD, and there
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may be a number of reasons for this. It is possible that MVD does not in fact play a 
significant prognostic role in Dukes’ C cancers. Neovascularization is essential for 
tumour proliferation or the growth of tumour cells [Folkman J, 1990] but the formation 
of new vessels, per se, may not necessarily have a causal relationship with 
development of metastases in colorectal cancers. MVD may determine the speed of 
tumour recurrence after the metastatic process has already been triggered by other 
more important factors. This hypothesis was also suggested by Sternfeld et al who 
also found no significant difference in overall survival between the two tumour groups 
with high and low MVD, using the same methodology as the current study [Sternfeld 
T et al., 1999]. However, in the sub-group of patients with recurrence, MVD was an 
independent prognostic factor and a stronger predictor of overall survival and 
relapse-free survival than conventional histological parameters. Their conclusion was 
that because the correlation of MVD with the more aggressive tumours is 
retrospective rather than prospective, it had no clinical value as a new prognostic 
marker. MVD was an important predictor of poor outcome only in those tumours 
where other, unknown mechanisms, had already triggered the metastatic process.
Ascertaining the density of microvessels in a tumour does not give any information 
regarding the integrity of the microvessels. The process whereby blood vessels 
become permeable to tumour cells, facilitating the metastatic process, is a complex 
one. It involves numerous molecular pathways which include interactions with cellular 
and humoral components of the immune/inflammatory system, coagulation 
molecules, intercellular adhesion molecules, and the enzymes involved in the 
integrity of surrounding connective tissue (e.g. proteases). Emerging characterization 
of the signal transduction pathways in endothelial cells indicates that there are also a 
number of endothelial growth factors which may act in concert in tumour
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angiogenesis and affect the metastatic process [Barozzi C et al., 2002; Viloria Petit 
AM et al., 1997].
Recent studies also suggest that tumour micro-vascularity is not the only process 
that may affect prognosis. The degree of vascular maturation varies between 
tumours, and this is independent of MVD [Eberhard A et al., 2000]. Furthermore the 
ability to maintain the newly formed vessels also varies among tumours. Endothelial 
cell proliferation occurs predominantly at the tumour periphery, as shown by Fox et 
al. [Fox SB et al., 1993]. As the tumour grows, the new vessels, which are formed in 
the invading edge, are gradually incorporated by the growing tumour. The ability of 
these vessels to survive will play an important role in the vascular density of the 
tumour, and may, independently of MVD, also affect its potential for metastasizing. 
The importance of vascular survival ability was recently demonstrated in a study 
which assessed this parameter in a sample of 242 colorectal cancers [Giatromanolaki 
A et al., 2002]. Vascular survival ability was the most significant independent 
prognostic variable (p=0.0001) on a multivariate analysis, followed by vascular 
invasion and Dukes’ stage. They also noted that there was no association between 
vascular survival ability and the MVD in a tumour, suggesting that the biological 
pathways controlling angiogenesis are not identical to those controlling vascular 
survival. In the same study, the MVD was not different among stage A, B, and C 
tumours, suggesting that the angiogenic activity of a tumour reaches its maximum in 
the early stages of development of the disease in colorectal cancer.
The lack of association between MVD and Dukes’ stage was also reported by Bossi 
etal. [Bossi P et al., 1995] who looked at the association between MVD and outcome 
in 178 Dukes’ A-D colorectal cancer patients. They used the same anti-CD31 mAb
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(JC-70) as in the current study, and also found no significant association between 
MVD and metastases or survival. They also found no association between MVD and 
stage of disease. However, they did demonstrate a significant progression in the 
MVD seen in normal bowel mucosa, adenomas and carcinomas of the colon, 
suggesting that although angiogenesis did not provide significant prognostic 
information in colorectal cancer patients, it was a critical step in colorectal 
tumourigenesis.
Of the 14 studies summarized in Table 6.2, nine performed multivariate analyses. Of 
these, four showed MVD to be an independent prognostic marker for survival, whilst 
four did not. In accordance with the former four studies, there is experimental 
evidence to show that as tumour neovascularization increases, the propensity for 
haematogenous spread of tumour cells also increases [Folkman J, 1994]. 
Furthermore, the association between increasing vascularity of a tumour and 
increased shedding of tumour cells into the vessels has been demonstrated 
[McCullough P et al., 1995]. However, one study, in 212 colorectal cancer patients, 
found the opposite to the findings in other studies. That is, a significantly longer 
survival time for patients who had tumours with a mean microvessel count of >10, as 
compared with those who had =s5 [Lindmark G et al., 1996]. Although a surprising 
finding, it is difficult to ignore this study which is the largest series looking at MVD in 
colorectal cancer, and it highlights the current controversy about the precise 
prognostic role of angiogenesis in colorectal cancer.
The difficulty in interpreting these studies is that they have all used varying 
methodologies, although in some cases, the differences are subtle. In assessing the 
MVD, many have used the methodology initially described by Weidner et al.
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[Weidner N et al., 1991], and subsequently recommended by the consensus paper 
[Vermeulen PB et al., 1996]. However, the differences in methodology between 
some of the studies make comparison of the results difficult. For example, although 
the magnification at which the microvessel count was performed was often the same 
(i.e. a magnification of 200X), some groups have deviated from this, and used field 
magnifications varying from 100X to 1000X to assess the vessel count, which means 
that the area of tumour over which the vessels are being counted are not 
comparable. Furthermore, there is no defined vessel count that automatically 
distinguishes a tumour with a high MVD from one with a low vessel count. Many 
investigators have used the median MVD, as the cut-off, to dichotomize the tumours 
into low and high MVD tumours, as recommended by the consensus paper 
[Vermeulen PB et al., 1996]. Others have used the mean microvessel count, or a 
random cut-off. Therefore the range of cut-offs for the low and high MVD groups 
from these studies vary from 28 to 254. Even in those studies which reported MVD to 
be an independent prognostic marker, the range of MVD used as the cut-off ranged 
from 55 to 105. The differences in the cut-offs is not accounted for by the different 
stages of disease in the various studies. Interpretation of all these results is difficult 
as there is significant overlap between the high and low MVD groups between the 
different studies.
The disparity seen among the different studies in terms of the prognostic role of 
MVD probably reflects the fact that the metastatic process is far too complex to look 
for one prognostic marker in isolation. In colorectal tumourigenesis, Fearon and 
Vogelstein proposed that colorectal cells must acquire between four and six 
molecular defects, including tumour suppressor gene inactivation and up-regulation 
of mutational oncogenes, and that it is the combination of these molecular events
Page 114
Chapter Six Discussion and Conclusion
which culminates in the transition from adenoma to carcinoma [Fearon ER and 
Vogelstein B, 2001]. Likewise, the continuing evolution of a tumour’s molecular 
make-up and the proliferation-apoptosis balance are influenced by a number of 
factors, which not only includes tumour angiogenesis but also includes cell-cell and 
cell-matrix adhesion, cancer cell motility and migration, and the host immune 
response. It is the interaction of all these factors, and others that will determine the 
metastatic potential of a tumour.
6.6 The Co-expression of HER-2 and MVD in Colorectal Cancer
In the current study, no significant association was seen between the overexpression 
of HER-2 and MVD in Dukes’ C colorectal cancer. It is thought that HER-2, through 
its mediation of the signal transduction pathways, may up-regulate the expression of 
one or more growth factors that function as stimulators of angiogenesis [Bouck N et 
al., 1996; Rak J et al., 1994]. One such factor is vascular endothelial growth factor, 
which is currently regarded as the major angiogenesis stimulator in human cancers 
[Ferrarra N, 1995;Folkman J, 1996].
The co-expression of HER-2 and angiogenic markers in tumours may yield more 
information regarding prognosis. There has been some work done on this in breast 
tumours, where again the results are variable. For example, in one report of ninety- 
nine invasive ductal cancers, MVD was significantly associated with p53, the other 
gene that is thought to be involved with VEGF expression. In this study, there was no 
association with HER-2 [Lee JS et al., 2002]. In another recent study looking at 77 
node-negative breast cancers, high MVD was significantly associated with HER-2 
overexpression, and high MVD was independently linked to relapse-free survival 
[Koukourakis Ml et al., 2003].
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In colorectal cancer, there have been few studies investigating the co-expression of 
MVD and HER-2. Berney et al looked at the significance of the combination 
expression of five protein markers in fifty-eight patients with Dukes’ A-C colorectal 
cancer. The five proteins were those believed to play a role in the development of 
colorectal cancer - c-erbB-2 protein product, the two tumour suppressor genes p53 
and nm23, and VEGF and urokinase-like plasminogen activator. They found that 
although co-expression of these five protein markers seemed to be related to an 
increased risk of developing liver secondaries in colorectal cancer, nm23 was the 
only independent prognostic marker [Berney CR et al., 1999].
Another group of investigators also looked at the relevance of a broad panel of 
biological markers, including VEGF and HER-2, in colorectal cancer patients [Barozzi 
C et al., 2002]. They found that the expression levels of HER-2 and VEGF were 
significantly higher in tumours which had metastasised, compared to those of 
patients who had achieved a disease-free survival of greater than six years.
The correlation between the various tumour protein markers must be diverse, and 
the interaction of these markers in the metastatic cascade equally complex. The use 
of microarray techniques and proteinomics to look at the co-expression of these 
proteins will hopefully facilitate more of these studies which may help to select out 
those protein markers that are an absolute pre-requisite to the metastatic process. If 
successful, this will ultimately allow the clinician to improve the selection of those 
patients who are at increased risk of developing metastatic disease. The recent work 
of Van’t Veer et al has shown an excellent example of how molecular profiling can 
accurately predict the outcome of breast cancer patients [van't Veer LJ et al., 2002].
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They used gene-expression microarrays, and were able to show that collectively 70 
marker genes could accurately predict whether a young node-negative breast cancer 
patient would relapse within 5 years. If in fact this type of molecular profiling does 
indeed improve prediction of recurrence of disease, its use in other tumour sites, 
such as colorectal cancer will be a great advantage not only in the selection of 
patients for adjuvant treatments, but in particular the development of more specific 
treatments to target some of these proteins.
However, the limitations of such microarray techniques must be borne in mind. With 
the high throughputs of such techniques, the quality control may suffer. For example, 
to generate a cDNA microarray, there are many error-prone steps -  PCR 
amplification, purification of DNA, and transfer of DNA into 384-well plates for 
printing. It is thought that for greater than 10% of cDNA arrays, the DNA on the 
microarray is not what the label says it is. Furthermore, the high cost of microarrays 
has tended to prohibit replication of experiments to confirm results. Other 
considerations include tumour heterogeneity, resulting in different genetic profiles 
within the same tumour, and the final interpretation of the mound of data from 
genomics and proteomics to biologically meaningful information [Zhang W et al., 
2001]. After all, the detection of a specific protein within a tumour may be of 
prognostic value, but may be of limited value as a therapeutic target.
6.7 Anti-Angiogenic Therapy
Targeting the endothelial cells that line the tumour blood vessels is a new anticancer 
strategy. Bevacizumab is an inhibitor of vascular endothelial growth factor. It has 
been combined with conventional chemotherapy (5-FU/FA) in a phase II randomized
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trial in metastatic colorectal cancer patients. This combination has shown significant 
results with improved response rates and longer median survival in the 5-FU/FA 
alone arm [Kabbinavar F et al., 2003]. The ability of this anti-VEGF mAb to prolong 
survival in this trial has given credence to this anti-angiogenic approach, but there 
are still unanswered questions regarding the selection of patients for such 
treatments, and the method of determining MVD in tumours if this is deemed 
necessary. Despite the continued uncertainty of the prognostic significance of 
tumour MVD, bevacizumab has now (February 2004) been approved to be used in 
combination with intravenous 5-FU-based chemotherapy as a treatment for patients 
with previously untreated metastatic colorectal cancer.
6.8 Concluding Remarks and Future Considerations
Tumour heterogeneity means that combination therapies are needed to prevent 
sub-optimal treatments. However, the current low improvement in survival 
(approximately 6% at 5 years) seen with conventional adjuvant combination 
chemotherapies is strong evidence that more molecular targets with a significant role 
in the proliferation, invasion and metastatic behaviour of tumours are needed. The 
explosive development of molecular genetic techniques has led to the identification 
of key proteins that regulate normal biological processes. These proteins may give 
us further vital information about the expected behaviour of a particular cancer and 
improve the selection of patients for whom adjuvant treatment has a definite survival 
advantage. The difficult task is in deciphering the relative importance of these 
cellular proteins in the mitogenic process. The therapeutic goal is to capitalise on this 
new information and translate it into more tumour selective therapies that will 
demonstrate not only greater efficacy, but also less toxicity than current ones.
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It will be important to validate the prognostic role of cytoplasmic HER-2 in a 
prospective study. Standardization of the HER-2 immunohistochemistry method and 
assessment is of vital importance in colorectal cancer if this question is to be 
answered. In addition, the relative contribution of other growth factor receptors to the 
malignant behaviour of human colorectal cancer warrants further investigation. 
Indeed, an assessment of other growth factor receptors is currently underway in the 
same group of colorectal cancer patients. The receptors being investigated include 
wild-type EGFR, activated (phosphorylated) EGFR, EGFR VIII, phosphorylated 
tyrosine kinase proteins (pTyr-proteins), and IGF-1 R. There are few reports of 
tyrosine phosphorylation and the biological characteristics of a tumour. In lung 
cancer, it has been shown that overexpression of pTyr-proteins is associated with a 
poor disease-free survival in spite of the absence of correlation with clinico- 
pathological factors [Gong Y et al., 2002]. The aim is to examine the level of co­
expression of all these receptors in colorectal cancer, and their prognostic role. In 
addition, the effect of simultaneous blockade of these various growth factors on the 
malignant behaviour of such tumours will be examined. Such studies, in turn, will 
also help to unravel whether simultaneous targeting of such receptors is more 
effective in the treatment of colorectal cancer patients.
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